{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/MananShukla7/SkimLit/blob/main/skimlit.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#Project : SkimLitüìùüî•\n",
        "\n",
        "`Short for Skimming Literature`\n",
        "\n",
        "The purpose of this notebook is to build a NLP model to make reading medical abstracts\n",
        "a lot easier\n",
        "\n",
        "The Dataset that we are using is PubMed 200k RCT and the paper we are replicating is :\n",
        "https://arxiv.org/abs/1710.06071\n",
        "\n"
      ],
      "metadata": {
        "id": "f5Wtz0v3JfiU"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Confirming access to GPU"
      ],
      "metadata": {
        "id": "f3OkofP3JhS4"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!nvidia-smi"
      ],
      "metadata": {
        "id": "nt2jg2siMAn0",
        "outputId": "0227b616-34c1-4d2d-9e1d-346bca706d9f",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/bin/bash: nvidia-smi: command not found\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Getting Data\n",
        "\n",
        "Downloading the dataset from the paper's author: https://github.com/Franck-Dernoncourt/pubmed-rct"
      ],
      "metadata": {
        "id": "zx1_tz6dMCtY"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!git clone https://github.com/Franck-Dernoncourt/pubmed-rct\n",
        "!ls pubmed-rct"
      ],
      "metadata": {
        "id": "nwuTSmjkNPes",
        "outputId": "aa2a1010-e39a-43e9-b35e-3112d5192d00",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Cloning into 'pubmed-rct'...\n",
            "remote: Enumerating objects: 33, done.\u001b[K\n",
            "remote: Counting objects: 100% (8/8), done.\u001b[K\n",
            "remote: Compressing objects: 100% (3/3), done.\u001b[K\n",
            "remote: Total 33 (delta 5), reused 5 (delta 5), pack-reused 25\u001b[K\n",
            "Unpacking objects: 100% (33/33), 177.08 MiB | 13.15 MiB/s, done.\n",
            "PubMed_200k_RCT\n",
            "PubMed_200k_RCT_numbers_replaced_with_at_sign\n",
            "PubMed_20k_RCT\n",
            "PubMed_20k_RCT_numbers_replaced_with_at_sign\n",
            "README.md\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Check what filer are in the PubMed 20k dataset\n",
        "!ls /content/pubmed-rct/PubMed_20k_RCT_numbers_replaced_with_at_sign/"
      ],
      "metadata": {
        "id": "R0P4oTPNNeAZ",
        "outputId": "47075ea1-bd3f-489a-d601-dc5fdb273cd9",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "dev.txt  test.txt  train.txt\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#Start our experiments by exploring and experimenting on 20k dataset!\n",
        "data_dir=\"/content/pubmed-rct/PubMed_20k_RCT_numbers_replaced_with_at_sign\""
      ],
      "metadata": {
        "id": "N3cAwO1vN5rs"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#Check all of the filename of its directory\n",
        "import os\n",
        "filenames=[data_dir+\"/\"+filename for filename in os.listdir(data_dir)]\n",
        "filenames"
      ],
      "metadata": {
        "id": "WbqcPkDbP0XM",
        "outputId": "4451ba1f-1459-420b-8f57-c6b1ca74e7ab",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['/content/pubmed-rct/PubMed_20k_RCT_numbers_replaced_with_at_sign/dev.txt',\n",
              " '/content/pubmed-rct/PubMed_20k_RCT_numbers_replaced_with_at_sign/train.txt',\n",
              " '/content/pubmed-rct/PubMed_20k_RCT_numbers_replaced_with_at_sign/test.txt']"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Data Preprocessing\n",
        "\n",
        "Now we've got some text data, now we have to explore it throughly.\n",
        "\n",
        "To do that we need to visualise it first."
      ],
      "metadata": {
        "id": "LjNIWXwOQGc1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "#Reading the files with python\n",
        "\n",
        "def get_lines(filename):\n",
        "  \"\"\"\n",
        "  Reads the filename (a text filename) and returns all of the lines of the text file\n",
        "  as a list.\n",
        "\n",
        "  Args:\n",
        "  filname: a string containing the target filepath\n",
        "\n",
        "  Returns:\n",
        "  A list of string with one string per line from the input text line\n",
        "  \"\"\"\n",
        "  f=open(filename,\"r\")\n",
        "  return f.readlines()\n",
        "\n"
      ],
      "metadata": {
        "id": "8Kc-tUL-QeKl"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Let's read into the training lines\n",
        "train_dir=filenames[1]\n",
        "train_lines=get_lines(train_dir)\n",
        "train_lines[:20]"
      ],
      "metadata": {
        "id": "hoS-O84KTF5r",
        "outputId": "dbed84b0-9b48-4e46-ffc4-99f031a1d9aa",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['###24293578\\n',\n",
              " 'OBJECTIVE\\tTo investigate the efficacy of @ weeks of daily low-dose oral prednisolone in improving pain , mobility , and systemic low-grade inflammation in the short term and whether the effect would be sustained at @ weeks in older adults with moderate to severe knee osteoarthritis ( OA ) .\\n',\n",
              " 'METHODS\\tA total of @ patients with primary knee OA were randomized @:@ ; @ received @ mg/day of prednisolone and @ received placebo for @ weeks .\\n',\n",
              " 'METHODS\\tOutcome measures included pain reduction and improvement in function scores and systemic inflammation markers .\\n',\n",
              " 'METHODS\\tPain was assessed using the visual analog pain scale ( @-@ mm ) .\\n',\n",
              " 'METHODS\\tSecondary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index scores , patient global assessment ( PGA ) of the severity of knee OA , and @-min walk distance ( @MWD ) .\\n',\n",
              " 'METHODS\\tSerum levels of interleukin @ ( IL-@ ) , IL-@ , tumor necrosis factor ( TNF ) - , and high-sensitivity C-reactive protein ( hsCRP ) were measured .\\n',\n",
              " 'RESULTS\\tThere was a clinically relevant reduction in the intervention group compared to the placebo group for knee pain , physical function , PGA , and @MWD at @ weeks .\\n',\n",
              " 'RESULTS\\tThe mean difference between treatment arms ( @ % CI ) was @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; and @ ( @-@ @ ) , p < @ , respectively .\\n',\n",
              " 'RESULTS\\tFurther , there was a clinically relevant reduction in the serum levels of IL-@ , IL-@ , TNF - , and hsCRP at @ weeks in the intervention group when compared to the placebo group .\\n',\n",
              " 'RESULTS\\tThese differences remained significant at @ weeks .\\n',\n",
              " 'RESULTS\\tThe Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International responder rate was @ % in the intervention group and @ % in the placebo group ( p < @ ) .\\n',\n",
              " 'CONCLUSIONS\\tLow-dose oral prednisolone had both a short-term and a longer sustained effect resulting in less knee pain , better physical function , and attenuation of systemic inflammation in older patients with knee OA ( ClinicalTrials.gov identifier NCT@ ) .\\n',\n",
              " '\\n',\n",
              " '###24854809\\n',\n",
              " 'BACKGROUND\\tEmotional eating is associated with overeating and the development of obesity .\\n',\n",
              " 'BACKGROUND\\tYet , empirical evidence for individual ( trait ) differences in emotional eating and cognitive mechanisms that contribute to eating during sad mood remain equivocal .\\n',\n",
              " 'OBJECTIVE\\tThe aim of this study was to test if attention bias for food moderates the effect of self-reported emotional eating during sad mood ( vs neutral mood ) on actual food intake .\\n',\n",
              " 'OBJECTIVE\\tIt was expected that emotional eating is predictive of elevated attention for food and higher food intake after an experimentally induced sad mood and that attentional maintenance on food predicts food intake during a sad versus a neutral mood .\\n',\n",
              " 'METHODS\\tParticipants ( N = @ ) were randomly assigned to one of the two experimental mood induction conditions ( sad/neutral ) .\\n']"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(train_lines)"
      ],
      "metadata": {
        "id": "Gdn2ldMiUBvm",
        "outputId": "d8655363-cc49-4461-ae1d-5f98b3eab5fc",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "210040"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "###Data Structuring\n",
        "\n",
        "Representing this data into dictionaries as it is easily manipulated.\n",
        "\n",
        "A sample structure would look like:\n",
        "\n",
        "```[{'line_number' : 0,\n",
        "   'target' : 'BACKGROUND',\n",
        "   'text' : 'Emotional eating is associated with overeating and the development of obesity .\\n',\n",
        "   'total_lines' : 11, \n",
        "   ...\n",
        "   }]```"
      ],
      "metadata": {
        "id": "toyERzUDUDuq"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def preprocess_text_with_line_num(txtData):\n",
        "  types=[\"BACKGROUND\", \"OBJECTIVE\", \"METHODS\", \"RESULTS\", \"CONCLUSION\"]\n",
        "  linecount=0\n",
        "  data=dict()\n",
        "  for txt in txtData:\n",
        "    if \"###\" in txt:\n",
        "        start_index=txtData.index(txt)\n",
        "        end_index=txtData.index(\"\\n\",start_index)\n",
        "        total_lines=end_index-start_index\n",
        "        # dict.update()\n",
        "    # elif \"\\n\"==txtData:\n",
        "    #   continue\n",
        "    else:\n",
        "      for typ in types:\n",
        "        if typ in txt:\n",
        "          target=typ\n",
        "\n",
        "      start=txt.find(\"\\t\")\n",
        "      end=txt.find(\".\\n\")\n",
        "      text=txt[start:end+1]\n",
        "      \n",
        "      \n",
        "      \n",
        "\n",
        "      update_val={\"line_number\":linecount,\n",
        "                  \"target\":target,\n",
        "                  \"text\":text,\n",
        "                  \"total_line\":total_lines}\n",
        "      data.update(update_val)\n",
        "      print(f\"[line_number:{linecount},\\ntarget:{target},\\ntext:{text},\\ntotal_line:{total_lines}]\\n\\n\")\n",
        "    linecount+=1\n",
        "\n",
        "  \n",
        "\n",
        "\n",
        "\n",
        "\n",
        "  \n",
        "    \n",
        "    "
      ],
      "metadata": {
        "id": "rBa4bjjeVrtY"
      },
      "execution_count": 34,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "d=preprocess_text_with_line_num(train_lines)\n",
        "d"
      ],
      "metadata": {
        "id": "D8DQjZcbd8Oy",
        "outputId": "25a67c65-5789-47e3-9579-c65ebd119a43",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "execution_count": 37,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "\n",
            "\n",
            "[line_number:39952,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39954,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe international multicentre FAME Study ( n = @,@ ) demonstrated significant health benefits for patients undergoing multivessel percutaneous coronary intervention ( PCI ) guided by fractional flow reserve ( FFR ) measurement compared with angiography guidance alone ( ANGIO ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39955,\n",
            "target:OBJECTIVE,\n",
            "text:\tWe determined the cost-effectiveness and the public health/budget impact for Australia .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39956,\n",
            "target:METHODS,\n",
            "text:\tWe performed a prospective economic evaluation comparing FFR vs. ANGIO in patients with multivessel disease based on original patient-level FAME data .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39957,\n",
            "target:METHODS,\n",
            "text:\tWe used Australian utilities ( EQ-@D ) and costs to calculate quality-adjusted life years ( QALYs ) and incremental cost-effectiveness adopting the societal perspective .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39958,\n",
            "target:METHODS,\n",
            "text:\tThe public health and budget impact from the payer 's perspective was based on Australian PCI registries .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39959,\n",
            "target:METHODS,\n",
            "text:\tUncertainty was explored using deterministic sensitivity analyses and the bootstrap method ( n = @,@ samples ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39960,\n",
            "target:RESULTS,\n",
            "text:\tThe cost-effectiveness analysis showed that FFR was cost-saving and reduces costs by @,@ AUD per patient during one year .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39961,\n",
            "target:RESULTS,\n",
            "text:\tOver a two-year time horizon , the public health impact ranged from @ to @ QALYs gained and the budget impact from @ to @ million AUD total cost savings .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39962,\n",
            "target:RESULTS,\n",
            "text:\tSensitivity analyses demonstrated that FFR was cost-saving over a wide range of assumptions .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39963,\n",
            "target:CONCLUSION,\n",
            "text:\tFFR-guided PCI in patients with multivessel coronary disease substantially reduces cardiac events , improves QALYs and is cost-saving in the Australian health care system .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39964,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:39966,\n",
            "target:BACKGROUND,\n",
            "text:\tThis study aimed to evaluate the feasibility of non-contrast-enhanced @D magnetic resonance angiography ( NCE @D MRA ) with signal targeting with alternative radiofrequency ( STAR ) spin labeling and variable flip angle ( VFA ) sampling in the assessment of dural arteriovenous fistula ( DAVF ) in the transverse sinus .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39967,\n",
            "target:METHODS,\n",
            "text:\tNine patients underwent NCE @D MRA for the evaluation of DAVF in the transverse sinus at @T .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39968,\n",
            "target:METHODS,\n",
            "text:\tOne patient was examined twice , once before and once after the interventional treatment .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39969,\n",
            "target:METHODS,\n",
            "text:\tAll patients also underwent digital subtraction angiography ( DSA ) and/or contrast-enhanced magnetic resonance angiography ( CEMRA ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39970,\n",
            "target:METHODS,\n",
            "text:\tFor the acquisition of NCE @D MRA , a STAR spin tagging method was used , and a VFA sampling was applied in the data readout module instead of a constant flip angle .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39971,\n",
            "target:METHODS,\n",
            "text:\tTwo readers evaluated the NCE @D MRA data for the diagnosis of DAVF and its type with consensus .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39972,\n",
            "target:METHODS,\n",
            "text:\tThe results were compared with those from DSA and/or CEMRA .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39973,\n",
            "target:RESULTS,\n",
            "text:\tAll patients underwent NCE @D MRA without any difficulty .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39974,\n",
            "target:RESULTS,\n",
            "text:\tAmong seven patients with patent DAVFs , all cases showed an early visualization of the transverse sinus on NCE @D MRA .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39975,\n",
            "target:RESULTS,\n",
            "text:\tExcept for one case , the type of DAVF of NCE @D MRA was agreed with that of reference standard study .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39976,\n",
            "target:RESULTS,\n",
            "text:\tCortical venous reflux ( CVR ) was demonstrated in two cases out of three patients with CVR .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39977,\n",
            "target:CONCLUSION,\n",
            "text:\tNCE @D MRA with STAR tagging and VFA sampling is technically and clinically feasible and represents a promising technique for assessment of DAVF in the transverse sinus .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39978,\n",
            "target:CONCLUSION,\n",
            "text:\tFurther technical developments should aim at improvements of spatial and temporal coverage .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39979,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:39981,\n",
            "target:BACKGROUND,\n",
            "text:\tNon-cystic fibrosis bronchiectasis is characterized by the irreversible dilatation of the medium-sized bronchi as a result of airway injury from recurrent or chronic inflammation and lower respiratory tract infections .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39982,\n",
            "target:BACKGROUND,\n",
            "text:\tBronchiectasis airways are commonly colonized with bacterial species .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39983,\n",
            "target:BACKGROUND,\n",
            "text:\tInfections of the airways play important role in bronchiectasis exacerbations .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39984,\n",
            "target:BACKGROUND,\n",
            "text:\tThe non-specific prevention of recurrent airway infections by immunostimulating agents has gained growing interest .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39985,\n",
            "target:BACKGROUND,\n",
            "text:\tOM-@ , consisting of extracts of eight kinds of bacteria important in respiratory infections , could support the respiratory tract resistance to the pathogens .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39986,\n",
            "target:BACKGROUND,\n",
            "text:\tOM-@ has been shown to be a benefit by decreasing the risk of acute exacerbation of chronic obstructive pulmonary disease ( COPD ) in several perspective clinical trials .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39987,\n",
            "target:BACKGROUND,\n",
            "text:\tExacerbation of bronchiectasis substantially contributes to a more rapid decline in lung function , reduced quality of life , and healthcare costs .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39988,\n",
            "target:BACKGROUND,\n",
            "text:\tIn this context , we plan to conduct a clinical trial to investigate the PReventive effect of OM-@ on Bronchiectasis Exacerbation in Chinese patients ( iPROBE ) .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39989,\n",
            "target:METHODS,\n",
            "text:\tThis study is designed as a prospective , randomized , double blind , placebo-controlled multicenter trial .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39990,\n",
            "target:METHODS,\n",
            "text:\tA total of @ patients with bronchiectasis , who have had at least one exacerbation of bronchiectasis in the previous year , will be included .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39991,\n",
            "target:METHODS,\n",
            "text:\tThe subjects will randomly receive two courses of @ mg of OM-@ or a matching placebo .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39992,\n",
            "target:METHODS,\n",
            "text:\tThe treatment dose of OM-@ will be one daily capsule taken orally for @ days each month for @ consecutive months at the beginning of the study , followed by @ months of no drug .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39993,\n",
            "target:METHODS,\n",
            "text:\tThis schedule will repeat until the patient has been seen for one year .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39994,\n",
            "target:CONCLUSION,\n",
            "text:\tWe will investigate whether long-term treatment with an oral immunostimulant ( OM-@ ) could decrease exacerbations of bronchiectasis over a one-year period .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39995,\n",
            "target:CONCLUSION,\n",
            "text:\tWe will also assess other relevant outcomes , including the rate of event-based exacerbation , lung function parameters , and total scores judged by the St George 's respiratory questionnaire , Leicester cough questionnaire , and inflammatory index .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39996,\n",
            "target:CONCLUSION,\n",
            "text:\tWe hope that this study will provide new information on the preventive effects of OM-@ on bronchiectasis exacerbations and will address a knowledge gap for this understudied disease .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39997,\n",
            "target:BACKGROUND,\n",
            "text:\tThis study is registered at http://www.clinicaltrials.gov ( identifier NCT@ ) on @ October @ .,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:39998,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:18]\n",
            "\n",
            "\n",
            "[line_number:40000,\n",
            "target:BACKGROUND,\n",
            "text:\tDipeptidyl peptidase ( DPP ) -@ inhibitors and sulfonylureas may have different effects on islet function .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40001,\n",
            "target:BACKGROUND,\n",
            "text:\tWe designed a new two-step hyperglycemic clamp to further compare the effects of sitagliptin , saxagliptin , and glimepiride on - cell function and the incretin effect .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40002,\n",
            "target:METHODS,\n",
            "text:\tThe present study was a four-way cross-over open label randomized study .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40003,\n",
            "target:METHODS,\n",
            "text:\tTwelve healthy male subjects were administered a single dose of sitagliptin ( @mg ) , saxagliptin ( @mg ) , glimepiride ( @mg ) or blank control @h before undergoing a two-step hyperglycemic clamp ( Step @ : only intravenous glucose was administered ; Step @ : i.v. glucose loading was combined with oral glucose consumption ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40004,\n",
            "target:METHODS,\n",
            "text:\tTwo-phase insulin secretion , glucagon secretion , and incretin levels were measured during the clamp .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40005,\n",
            "target:RESULTS,\n",
            "text:\tIn Step @ , with i.v. glucose only , there were no differences between the effects of the three drugs on insulin secretion , except that saxagliptin increased second-phase insulin secretion more than glimepiride ( P = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40006,\n",
            "target:RESULTS,\n",
            "text:\tIn Step @ , oral glucose consumption led to an approximate two fold increase in insulin secretion and both gliptins significantly increased first-phase insulin secretion compared with glimepiride ( P = @ for both ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40007,\n",
            "target:RESULTS,\n",
            "text:\tSaxagliptin further increased second-phase insulin secretion compared with glimepiride ( P = @ ) and sitagliptin ( P < @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40008,\n",
            "target:RESULTS,\n",
            "text:\tBoth gliptins significantly decreased glucagon secretion and increased active glucagon-like peptide-@ ( GLP-@ ) compared with glimepiride , especially in Step @ .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40009,\n",
            "target:CONCLUSION,\n",
            "text:\tThe two-step hyperglycemic clamp appears to be a precise method to assess - cell function by taking the effect of incretins into consideration .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40010,\n",
            "target:CONCLUSION,\n",
            "text:\tThe oral glucose consumption adds to the i.v. glucose infusion , amplifying the differences in the effects of DPP-@ inhibitors and glimepiride on insulin secretion .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40011,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40013,\n",
            "target:OBJECTIVE,\n",
            "text:\tExercise induces oxidative stress and causes adaptations in antioxidant defenses .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40014,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe aim of the present study was to determine the effects of a @-month diet supplementation with docosahexaenoic acid ( DHA ) on the pro-oxidant and antioxidant status of peripheral blood mononuclear cells ( PBMCs ) during football training and after acute exercise .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40015,\n",
            "target:METHODS,\n",
            "text:\tFifteen male football players , in a randomized double-blind trial , ingested a beverage enriched with DHA or a placebo for @ weeks .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40016,\n",
            "target:METHODS,\n",
            "text:\tBlood samples were collected in basal conditions before and after the training period and after an acute and intense exercise .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40017,\n",
            "target:RESULTS,\n",
            "text:\tThe training season increased the carbonyl and nitrotyrosine index but decreased the malondialdehyde ( MDA ) levels .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40018,\n",
            "target:RESULTS,\n",
            "text:\tBasal catalase activity decreased in both groups after @ weeks of training , whereas glutathione peroxidase activity increased mainly in the placebo group .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40019,\n",
            "target:RESULTS,\n",
            "text:\tProtein levels of uncoupling proteins ( UCP@ and UCP@ ) and inducible nitric oxide synthase significantly increased after the training period .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40020,\n",
            "target:RESULTS,\n",
            "text:\tAcute exercise induced redistribution in the number of circulating cells , increased the MDA levels and nitrotyrosine index , and decreased the levels of nitrate .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40021,\n",
            "target:RESULTS,\n",
            "text:\tAcute exercise also increased PBMCs reactive oxygen species ( ROS ) production after immune stimulation .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40022,\n",
            "target:RESULTS,\n",
            "text:\tDiet supplementation with DHA significantly increased the UCP@ levels after training and the superoxide dismutase protein levels after acute exercise , and reduced the production of ROS after acute exercise .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40023,\n",
            "target:CONCLUSION,\n",
            "text:\tDocosahexaenoic acid increased the antioxidant capabilities while reducing the mitochondrial ROS production in a regular football training period and reduced the oxidative damage markers in response to acute exercise .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40024,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40026,\n",
            "target:METHODS,\n",
            "text:\tProspective randomized study .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40027,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo compare autologous bone marrow concentrate mixed with allograft cancellous bone to iliac crest autograft in lumbar fusions .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40028,\n",
            "target:BACKGROUND,\n",
            "text:\tBone marrow has been shown to be a rich source of osteoprogenitor cells .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40029,\n",
            "target:BACKGROUND,\n",
            "text:\tOsteoprogenitor cells have been shown in animals , and some human studies , to have potential in use as a bone graft substitute .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40030,\n",
            "target:METHODS,\n",
            "text:\tTwenty-five patients underwent from @ - to @-level lumbar fusions .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40031,\n",
            "target:METHODS,\n",
            "text:\tOne patient was lost to follow-up .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40032,\n",
            "target:METHODS,\n",
            "text:\tOn one half of the spine , allograft plus autologous bone marrow concentrate was used , whereas on the other half , autologous iliac crest bone was used .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40033,\n",
            "target:METHODS,\n",
            "text:\tCellular analysis , consisting of nucleated cell count , mononuclear cell count , CD@ + count , and colony-forming-units-fibroblast count , was done on marrow aspirates and concentrates .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40034,\n",
            "target:METHODS,\n",
            "text:\tAt @ year postoperation , computed tomographic scans of the fusions were evaluated on a blinded basis by @ neuroradiologists independent of each other .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40035,\n",
            "target:METHODS,\n",
            "text:\tRadiographical fusion was the primary outcome measure .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40036,\n",
            "target:RESULTS,\n",
            "text:\tThere was no statistical difference in fusion scores between allograft and autograft in the lateral gutters , interbody cages , or facet joints .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40037,\n",
            "target:RESULTS,\n",
            "text:\tThere was a positive trend between CD@ + counts and radiographical fusion .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40038,\n",
            "target:CONCLUSION,\n",
            "text:\tThe study shows equivalence between cancellous allograft mixed with bone marrow concentrate and autologous iliac crest bone for lumbar fusions .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40039,\n",
            "target:METHODS,\n",
            "text:\t@ .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40040,\n",
            "target:METHODS,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40042,\n",
            "target:BACKGROUND,\n",
            "text:\tPlatinum-resistant ovarian cancer ( PROC ) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40043,\n",
            "target:BACKGROUND,\n",
            "text:\tBased on prior data suggesting that scheduling alterations of platinum would increase activity , the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC@-carboplatin in PROC patients .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40044,\n",
            "target:METHODS,\n",
            "text:\tA multicenter randomized double-blind placebo controlled phase-III-study was conducted to compare oral PXD plus AUC@-carboplatin ( group @ ) versus placebo plus AUC@-carboplatin ( group @ ) weekly in PROC patients .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40045,\n",
            "target:METHODS,\n",
            "text:\tThe primary end point was progression-free-survival ( PFS ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40046,\n",
            "target:METHODS,\n",
            "text:\tSecondary objectives included overall survival ( OS ) , response rates , duration of response and quality of life .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40047,\n",
            "target:RESULTS,\n",
            "text:\tThe study was terminated early @ April @ , after recruitment of @ patients due to feasibility and recruitment challenges .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40048,\n",
            "target:RESULTS,\n",
            "text:\tA total of @ patients were randomized .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40049,\n",
            "target:RESULTS,\n",
            "text:\tThe groups were well balanced in terms of important baseline characteristics .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40050,\n",
            "target:RESULTS,\n",
            "text:\tThe median PFS for group @ was @ weeks -LSB- @ % confidence interval ( CI ) @-@ @ -RSB- versus @ weeks for group @ ( @ % CI = @-@ @ ) ; P = @ .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40051,\n",
            "target:RESULTS,\n",
            "text:\tThe objective response rate and median survival in group @ versus group @ was @ % versus @ % and @ weeks ( @ % CI @-@ @ ) versus @ weeks ( @ % CI @-@ @ ) , respectively .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40052,\n",
            "target:RESULTS,\n",
            "text:\tPXD appeared to be well tolerated .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40053,\n",
            "target:RESULTS,\n",
            "text:\tThe main reason for dose modification in both groups was hematologic toxicity .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40054,\n",
            "target:CONCLUSION,\n",
            "text:\tOrally delivered PXD showed no evidence of clinical activity , when combined with weekly AUC@-carboplatin in PROC .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40055,\n",
            "target:CONCLUSION,\n",
            "text:\tIn addition , single-agent weekly AUC@-carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40056,\n",
            "target:CONCLUSION,\n",
            "text:\tThis has implications for the design of future studies .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40057,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40059,\n",
            "target:BACKGROUND,\n",
            "text:\tLeft-ventricular ejection fraction ( LVEF ) is regarded as a strong predictor for morbidity and mortality in heart failure patients .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40060,\n",
            "target:BACKGROUND,\n",
            "text:\tThe aim of the analysis was to assess the relationship between pre-implant LVEF and outcome of patients with advanced heart failure who received cardiac resynchronization therapy ( CRT ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40061,\n",
            "target:METHODS,\n",
            "text:\tWe analysed the two-year follow-up of @ patients who had been enrolled in the MASCOT study which included NYHA class III/IV patients with a class I CRT indication .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40062,\n",
            "target:METHODS,\n",
            "text:\tPre-implant LVEF was stratified by tertile .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40063,\n",
            "target:RESULTS,\n",
            "text:\tThe boundaries for pre-implant LVEF were < @ % ( n = @ ; @ + / - @ % ; T ( low ) ) , @ % to @ % ( n = @ ; @ + / - @ % ; T ( middle ) ) and > @ % ( n = @ ; @ + / - @ % ; T ( high ) ) for each tertile.Two-year post-implant LVEF was @ + / - @ % ( T ( low ) ) , @ + / - @ % ( T ( middle ) ) and @ + / - @ % ( T ( high ) ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40064,\n",
            "target:RESULTS,\n",
            "text:\tT ( Iow ) had a greater increase between pre - and post-implant LVEF compared to T ( middle ) ( P = @ ) and T ( high ) ( P = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40065,\n",
            "target:RESULTS,\n",
            "text:\tNYHA class improved similarly among the three groups as well as the quality of life score .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40066,\n",
            "target:RESULTS,\n",
            "text:\tNo significant differences were detected between the three groups for all-cause mortality , cardiac death , all-cause hospitalization , and hospitalization due to worsening heart failure .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40067,\n",
            "target:CONCLUSION,\n",
            "text:\tSymptomatic heart failure patients with a wide QRS complex and a severe impaired LV function had a better improvement of their pre-implant LVEF than patients with a more preserved LVEF .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40068,\n",
            "target:CONCLUSION,\n",
            "text:\tThis may be one reason that in these patient groups long-term morbidity and mortality were not related to their pre-implant LVEF .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40069,\n",
            "target:CONCLUSION,\n",
            "text:\tPre-implant LVEF was in symptomatic CRT patients not predictive for their long-term cardiovascular morbidity and mortality .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40070,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40072,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo examine the antihypertensive effect of the synthetic analogue of the endogenous nitric oxide donors in patients with grades @-@ hypertension and uncomplicated hypertensive crisis ( HC ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40073,\n",
            "target:METHODS,\n",
            "text:\tThe study included @ male patients aged @ to @ years ( mean age @ @ years ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40074,\n",
            "target:METHODS,\n",
            "text:\tAll the patients had grades @-@ essential or secondary hypertension .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40075,\n",
            "target:METHODS,\n",
            "text:\tThirteen ( @ % ) patients were observed to have signs of HC ; @ ( @ % ) patients had persistent blood pressure ( BP ) elevation .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40076,\n",
            "target:METHODS,\n",
            "text:\tA dinitrosyl iron complex was injected in a dose of @ or @ mg per kg of body weight .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40077,\n",
            "target:METHODS,\n",
            "text:\tThe purpose of its administration was to lower BP by at least @ % of its baseline level .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40078,\n",
            "target:RESULTS,\n",
            "text:\tNo significant side effects associated with the administration of the test drug were recorded when the clinical trial protocol was implemented .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40079,\n",
            "target:RESULTS,\n",
            "text:\tAll the patients reported fever and facial hyperemia during and @-@ minutes after injection .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40080,\n",
            "target:RESULTS,\n",
            "text:\tThey all ( @ % ) showed efficient blood pressure reduction of at least @ % of the baseline level .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40081,\n",
            "target:RESULTS,\n",
            "text:\tBlood pressure changes were similar when the agent was administered in doses of @ or @ mg/kg .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40082,\n",
            "target:RESULTS,\n",
            "text:\tAt @-@ minutes after the drug was injected , there was a maximal decrease in blood pressure , then its gradual rise and stabilization at a lower level than the baseline one within the following @ hours .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40083,\n",
            "target:RESULTS,\n",
            "text:\tThere were no significant differences in the magnitude of a blood pressure reduction after administration of @ and @ mg/kg .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40084,\n",
            "target:CONCLUSION,\n",
            "text:\tThe findings suggest that the dinitrosyl iron complex is highly effective in treating uncomplicated HC .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40085,\n",
            "target:CONCLUSION,\n",
            "text:\tThe antihypertensive effect of the drug persists for @ hours after its injection , which is very important during prehospital therapy .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40086,\n",
            "target:CONCLUSION,\n",
            "text:\tThe drug is well tolerated by patients and causes an insignificant number of side effects .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40087,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40089,\n",
            "target:OBJECTIVE,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40090,\n",
            "target:OBJECTIVE,\n",
            "text:\tDetermine whether stress in preterm infants , measured with salivary cortisol , decreases after five days of Kangaroo Care ( KC ) compared to five days of Standard Care ( SC ) .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40091,\n",
            "target:OBJECTIVE,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40092,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo determine whether kangaroo care provides sustainable pain relief beyond the period of skin-to-skin holding .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40093,\n",
            "target:METHODS,\n",
            "text:\tPreterm infants ( n = @ ) born at @-@ weeks gestational age were randomized to either the KC or the SC group and received the allocated intervention starting on day of life ( DOL ) five and continuing for five days .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40094,\n",
            "target:METHODS,\n",
            "text:\tSalivary cortisol was collected on DOL five and again on DOL ten .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40095,\n",
            "target:METHODS,\n",
            "text:\tDifferences were analyzed using repeated measures ANOVA and t tests .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40096,\n",
            "target:METHODS,\n",
            "text:\tPain during nasal suctioning over five days was assessed using the Premature Infant Pain Profile ( PIPP ) .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40097,\n",
            "target:RESULTS,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40098,\n",
            "target:RESULTS,\n",
            "text:\tAdequate saliva samples for salivary cortisol were collected for @ KC infants and @ SC infants .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40099,\n",
            "target:RESULTS,\n",
            "text:\tThere was no main effect of group ( p = @ ) , but there was a significant main effect of age ( DOL five versus DOL ten ) , with salivary cortisol levels decreasing in both groups ( p = @ ) .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40100,\n",
            "target:RESULTS,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40101,\n",
            "target:RESULTS,\n",
            "text:\tPain scores for both groups ( n = @ ) indicted mild to moderate pain during suctioning , with no significant difference in pain scores between groups .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40102,\n",
            "target:CONCLUSION,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40103,\n",
            "target:CONCLUSION,\n",
            "text:\tKC did not affect salivary cortisol levels in preterm neonates , but levels in both the KC and SC groups decreased over time from DOL five to ten .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40104,\n",
            "target:CONCLUSION,\n",
            "text:\tSalivary cortisol may vary with age of infant .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40105,\n",
            "target:CONCLUSION,\n",
            "text:\t@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40106,\n",
            "target:CONCLUSION,\n",
            "text:\tInfants experience pain during routine suctioning and may require pain management .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40107,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40109,\n",
            "target:BACKGROUND,\n",
            "text:\tDexamethasone ( DEXA ) is commonly used to reduce brain swelling during neurosurgical procedures .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40110,\n",
            "target:BACKGROUND,\n",
            "text:\tDEXA , however , has many side-effects that can increase the risks of post-operative complications .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40111,\n",
            "target:BACKGROUND,\n",
            "text:\tIn contrast , progesterone ( PRO ) has fewer side-effects and has been found to be neuroprotective on traumatic brain injury ( TBI ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40112,\n",
            "target:BACKGROUND,\n",
            "text:\tWhether PRO may be used as an alternative to DEXA during routine procedures has not been fully explored .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40113,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo compare the effects of DEXA and PRO on surgical brain injury ( SBI ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40114,\n",
            "target:METHODS,\n",
            "text:\tSeventy-five adult male Sprague Dawley rats were randomized into five groups : ( @ ) SBI + drug vehicle ( peanut oil , @ml kg ( -@ ) ) ; ( @ ) SBI + DEXA ( @mg kg ( -@ ) ) ; ( @ ) SBI + low-dose PRO ( @mg kg ( -@ ) ) ; ( @ ) SBI + high-dose PRO ( @mg kg ( -@ ) ) ; and ( @ ) sham SBI + drug vehicle .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40115,\n",
            "target:METHODS,\n",
            "text:\tMagnetic resonance imaging study and assessments of brain water content ( BWC ) , blood-brain barrier ( BBB ) permeability , cellular inflammatory responses and matrix metalloproteinase @ ( MMP-@ ) expression were conducted .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40116,\n",
            "target:RESULTS,\n",
            "text:\tThis model consistently resulted in increased BWC and BBB disruption .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40117,\n",
            "target:RESULTS,\n",
            "text:\tPRO reduced astrocyte and microglia responses and attenuated brain oedema with preservation of BBB .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40118,\n",
            "target:RESULTS,\n",
            "text:\tA significant down-regulation of MMP-@ expression occurred in the PRO @ group .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40119,\n",
            "target:CONCLUSION,\n",
            "text:\tPRO is as effective as DEXA in reducing brain oedema and inflammation following SBI ; @mg kg ( -@ ) of PRO was demonstrated to be more effective in relieving acute cellular inflammatory responses .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40120,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40122,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo assess in multiple sclerosis ( MS ) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation ( AHSCT ) vs mitoxantrone ( MTX ) on disease activity measured by MRI .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40123,\n",
            "target:METHODS,\n",
            "text:\tWe conducted a multicenter , phase II , randomized trial including patients with secondary progressive or relapsing-remitting MS , with a documented increase in the last year on the Expanded Disability Status Scale , in spite of conventional therapy , and presence of one or more gadolinium-enhancing ( Gd + ) areas .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40124,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomized to receive intense immunosuppression ( mobilization with cyclophosphamide and filgrastim , conditioning with carmustine , cytosine-arabinoside , etoposide , melphalan , and anti-thymocyte globulin ) followed by AHSCT or MTX @ mg every month for @ months .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40125,\n",
            "target:METHODS,\n",
            "text:\tThe primary endpoint was the cumulative number of new T@ lesions in the @ years following randomization .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40126,\n",
            "target:METHODS,\n",
            "text:\tSecondary endpoints were the cumulative number of Gd + lesions , relapse rate , and disability progression .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40127,\n",
            "target:METHODS,\n",
            "text:\tSafety and tolerability were also assessed .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40128,\n",
            "target:METHODS,\n",
            "text:\tTwenty-one patients were randomized and @ had postbaseline evaluable MRI scans .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40129,\n",
            "target:RESULTS,\n",
            "text:\tAHSCT reduced by @ % the number of new T@ lesions as compared to MTX ( rate ratio @ , p = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40130,\n",
            "target:RESULTS,\n",
            "text:\tIt also reduced Gd + lesions as well as the annualized relapse rate .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40131,\n",
            "target:RESULTS,\n",
            "text:\tNo difference was found in the progression of disability .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40132,\n",
            "target:CONCLUSION,\n",
            "text:\tIntense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40133,\n",
            "target:CONCLUSION,\n",
            "text:\tThe study was registered as EUDRACT No. @-@-@ .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40134,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40136,\n",
            "target:BACKGROUND,\n",
            "text:\tAntenatal corticosteroids for pregnant women at risk of preterm birth are among the most effective hospital-based interventions to reduce neonatal mortality .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40137,\n",
            "target:BACKGROUND,\n",
            "text:\tWe aimed to assess the feasibility , effectiveness , and safety of a multifaceted intervention designed to increase the use of antenatal corticosteroids at all levels of health care in low-income and middle-income countries .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40138,\n",
            "target:METHODS,\n",
            "text:\tIn this @-month , cluster-randomised trial , we randomly assigned ( @:@ ) rural and semi-urban clusters within six countries ( Argentina , Guatemala , India , Kenya , Pakistan , and Zambia ) to standard care or a multifaceted intervention including components to improve identification of women at risk of preterm birth and to facilitate appropriate use of antenatal corticosteroids .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40139,\n",
            "target:METHODS,\n",
            "text:\tThe primary outcome was @-day neonatal mortality among infants less than the @th percentile for birthweight ( a proxy for preterm birth ) across the clusters .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40140,\n",
            "target:METHODS,\n",
            "text:\tUse of antenatal corticosteroids and suspected maternal infection were additional main outcomes .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40141,\n",
            "target:METHODS,\n",
            "text:\tThis trial is registered with ClinicalTrials.gov , number NCT@ .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40142,\n",
            "target:RESULTS,\n",
            "text:\tThe ACT trial took place between October , @ , and March , @ ( start dates varied by site ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40143,\n",
            "target:RESULTS,\n",
            "text:\t@ intervention clusters with @,@ livebirths ( @ -LSB- @ % -RSB- less than @th percentile for birthweight ) and @ control clusters with @,@ livebirths ( @ -LSB- @ % -RSB- less than @th percentile ) completed follow-up .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40144,\n",
            "target:RESULTS,\n",
            "text:\t@ ( @ % ) of @ women in intervention clusters who delivered less-than-@th-percentile infants received antenatal corticosteroids , compared with @ ( @ % ) of @ in control clusters ( p < @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40145,\n",
            "target:RESULTS,\n",
            "text:\tAmong the less-than-@th-percentile infants , @-day neonatal mortality was @ per @ livebirths for the intervention group and @ per @ livebirths for the control group ( relative risk -LSB- RR -RSB- @ , @ % CI @-@ , p = @ ) and suspected maternal infection was reported in @ ( @ % ) of @ women in the intervention group and @ ( @ % ) of @ in the control group ( odds ratio -LSB- OR -RSB- @ , @-@ , p < @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40146,\n",
            "target:RESULTS,\n",
            "text:\tAmong the whole population , @-day neonatal mortality was @ per @ livebirths for the intervention group and @ per @ livebirths for the control group ( RR @ , @-@ , p = @ ) and suspected maternal infection was reported in @ ( @ % ) of @,@ women in the intervention group and @ ( @ % ) of @,@ in the control group ( OR @ , @-@ , p < @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40147,\n",
            "target:CONCLUSION,\n",
            "text:\tDespite increased use of antenatal corticosteroids in low-birthweight infants in the intervention groups , neonatal mortality did not decrease in this group , and increased in the population overall .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40148,\n",
            "target:CONCLUSION,\n",
            "text:\tFor every @ women exposed to this strategy , an excess of @ neonatal deaths occurred , and the risk of maternal infection seems to have been increased .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40149,\n",
            "target:BACKGROUND,\n",
            "text:\tEunice Kennedy Shriver National Institute of Child Health and Human Development .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40150,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40152,\n",
            "target:OBJECTIVE,\n",
            "text:\tThis study investigates the acute and longitudinal effects of resistance training on occupational muscle activity in office workers with chronic pain .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40153,\n",
            "target:METHODS,\n",
            "text:\t@ female office workers with chronic neck and shoulder pain participated for @ weeks in high-intensity elastic resistance training for @ minutes per day ( n = @ ) or in control receiving weekly email-based information on general health ( n = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40154,\n",
            "target:METHODS,\n",
            "text:\tElectromyography ( EMG ) from the splenius and upper trapezius was recorded during a normal workday .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40155,\n",
            "target:RESULTS,\n",
            "text:\tAdherence to training and control interventions were @ % and @ % , respectively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40156,\n",
            "target:RESULTS,\n",
            "text:\tCompared with control , training increased isometric muscle strength @ % ( P < @ ) and decreased neck/shoulder pain intensity by @ % ( P < @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40157,\n",
            "target:RESULTS,\n",
            "text:\tThe frequency of periods with complete motor unit relaxation ( EMG gaps ) decreased acutely in the hours after training .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40158,\n",
            "target:RESULTS,\n",
            "text:\tBy contrast , at @-week follow-up , training increased average duration of EMG gaps by @ % , EMG gap frequency by @ % and percentage time below @ % , and @ % EMGmax by @ % and @ % , respectively , during the workday in m. splenius .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40159,\n",
            "target:CONCLUSION,\n",
            "text:\tWhile resistance training acutely generates a more tense muscle activity pattern , the longitudinal changes are beneficial in terms of longer and more frequent periods of complete muscular relaxation and reduced pain .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40160,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40162,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo observe the curative effect of acupuncture intervention combined with hyperbaric oxygen chamber treatment for delayed encephalopathy in @ carbon monoxide ( CO ) poisoning patients .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40163,\n",
            "target:METHODS,\n",
            "text:\tA total of @ CO poisoning encephalopathy patients were randomized into control group ( n = @ ) and acupuncture group ( n = @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40164,\n",
            "target:METHODS,\n",
            "text:\tPatients of the two groups were all treated with medicines ( energy mixture solution , hormones , brain cell activators , calcium ion blockers , anti-inflammatory agents , etc. ) and hyperbaric oxygen treatment ( oxygen-inhaling for @ min/time ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40165,\n",
            "target:METHODS,\n",
            "text:\tMoreover , patients of the acupuncture group received acupuncture stimulation of bilateral Taixi ( KI @ ) , Xuanzhong ( GB @ ) , Hegu ( LI @ ) , Taichong ( LR @ ) , and Fengchi ( GB @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40166,\n",
            "target:METHODS,\n",
            "text:\tAll the treatments were conducted once daily for @ days .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40167,\n",
            "target:METHODS,\n",
            "text:\tThe therapeutic effect of the treatments for neurological function was assessed by NIH Stroke Scale ( NIHSS , @ points in total ; including @ items as consciousness , horizontal eye movement , visual power , visual field , facial muscular motion , limb movement , coordination movement , sensory and language levels , etc. ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40168,\n",
            "target:RESULTS,\n",
            "text:\tAfter the treatment , of the @ and @ cases in the control and acupuncture groups , @ and @ were cured , @ and @ experienced marked improvement , @ and @ were improved , and @ and @ invalid , with the effective rates being @ % and @ % , respectively .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40169,\n",
            "target:RESULTS,\n",
            "text:\tThe therapeutic effect of the acupuncture group was significantly superior to that of the control group ( P < @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40170,\n",
            "target:RESULTS,\n",
            "text:\tThe average NIHSS score was @ + / - @ in the acupuncture group , being significantly lower than that ( @ + / - @ ) in the control group ( P < @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40171,\n",
            "target:CONCLUSION,\n",
            "text:\tAcupuncture treatment can effectively strengthen the efficacy of hyperbaric oxygen therapy in the treatment of delayed encephalopathy caused by carbon monoxide poisoning .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40172,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40174,\n",
            "target:BACKGROUND,\n",
            "text:\tResults of randomised controlled trials of newborn ( age @-@ days ) vitamin A supplementation have been inconclusive .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40175,\n",
            "target:BACKGROUND,\n",
            "text:\tThe WHO is coordinating three large randomised trials in Ghana , India , and Tanzania ( Neovita trials ) .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40176,\n",
            "target:BACKGROUND,\n",
            "text:\tWe present the findings of the Neovita trial in Ghana .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40177,\n",
            "target:METHODS,\n",
            "text:\tThis study was a population-based , individually randomised , double-blind , placebo-controlled trial in the Brong Ahafo region of Ghana .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40178,\n",
            "target:METHODS,\n",
            "text:\tThe trial participants were infants aged at least @ h , identified at home or facilities on the day of birth or in the next @ days , able to feed orally , and likely to stay in the study area for at least @ months .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40179,\n",
            "target:METHODS,\n",
            "text:\tThey were randomly assigned ( ratio @:@ ) to receive either one oral dose of vitamin A ( @,@ IU ) or placebo immediately after recruitment .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40180,\n",
            "target:METHODS,\n",
            "text:\tThe research team and parents of the infants were masked to treatment assignment .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40181,\n",
            "target:METHODS,\n",
            "text:\tFollow-up home visits were undertaken every @ weeks , when data were recorded for deaths , facility use , and care seeking .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40182,\n",
            "target:METHODS,\n",
            "text:\tThe primary outcome was post-supplementation mortality to @ months of age .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40183,\n",
            "target:METHODS,\n",
            "text:\tAnalysis was by intention to treat .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40184,\n",
            "target:METHODS,\n",
            "text:\tPotential adverse events were recorded at @ and @ days after supplementation .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40185,\n",
            "target:METHODS,\n",
            "text:\tThis trial is registered with the Australian New Zealand Clinical Trials Registry ( ANZCTR ) CTRN@ .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40186,\n",
            "target:RESULTS,\n",
            "text:\tWe assessed @,@ livebirths for eligibility between Aug @ , @ , and Nov @ , @ .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40187,\n",
            "target:RESULTS,\n",
            "text:\tWe recruited @,@ newborn infants , with @,@ randomly assigned to receive vitamin A and @,@ to receive placebo .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40188,\n",
            "target:RESULTS,\n",
            "text:\tLoss to follow-up was low with vital status at @ months of age reported for @,@ ( @ % ) infants .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40189,\n",
            "target:RESULTS,\n",
            "text:\tWe recorded @ post-supplementation deaths to @ months of age in the vitamin A group ( mortality risk @ in @ supplemented infants ) and @ deaths in the placebo group ( mortality risk @ per @ supplemented infants ) , relative risk ( RR ) @ ( @ % CI @-@ ; p = @ ) and risk difference ( RD ) @ ( @ % CI -@ to @ ; p = @ ) .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40190,\n",
            "target:RESULTS,\n",
            "text:\tAdverse events within @ days of supplementation did not differ by trial group .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40191,\n",
            "target:RESULTS,\n",
            "text:\t@ infants died in the first @ days after supplementation ; @ ( @ % ) in the vitamin A and @ ( @ % ) in the placebo group ( risk ratio -LSB- RR -RSB- @ , @ % CI @-@ , p = @ ) .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40192,\n",
            "target:RESULTS,\n",
            "text:\t@ infants were reported to have a bulging fontanelle ; @ ( @ % ) in the vitamin A group and @ ( @ % ) in the placebo group ( RR @ , @-@ , p = @ ) .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40193,\n",
            "target:CONCLUSION,\n",
            "text:\tThe results of this trial do not support inclusion of newborn vitamin A supplementation as a child survival strategy in Ghana .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40194,\n",
            "target:BACKGROUND,\n",
            "text:\tBill & Melinda Gates Foundation grant to the WHO .,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40195,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:22]\n",
            "\n",
            "\n",
            "[line_number:40197,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo assess the efficacy of two embolic agents in the treatment of symptomatic uterine leiomyomas .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40198,\n",
            "target:METHODS,\n",
            "text:\tA randomized , prospective , single-center study enrolled @ women with symptomatic uterine leiomyomas .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40199,\n",
            "target:METHODS,\n",
            "text:\tUterine artery embolization ( UAE ) with spherical polyvinyl alcohol ( SPVA ) microspheres ( n = @ ; @-@ m and @-@ ,@ m ; near-stasis or stasis endpoint ) and tris-acryl gelatin ( TAG ) microspheres ( n = @ ; @-@ m ; `` pruned-tree '' endpoint ) was performed .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40200,\n",
            "target:METHODS,\n",
            "text:\tInfarction rates were calculated for the dominant tumor and for small ( < @ cm ) and large ( > @ cm ) nondominant tumors .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40201,\n",
            "target:METHODS,\n",
            "text:\tThe primary endpoint was tumor infarction at @ hours measured by contrast-enhanced magnetic resonance imaging assessed by a blinded reviewer .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40202,\n",
            "target:RESULTS,\n",
            "text:\tBaseline characteristics were similar between groups .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40203,\n",
            "target:RESULTS,\n",
            "text:\tThe primary endpoint was similar in both treatments ( @ % dominant tumor infarction ; SPVA .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40204,\n",
            "target:RESULTS,\n",
            "text:\t@ % ; TAG , @ % , P = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40205,\n",
            "target:RESULTS,\n",
            "text:\tComplete infarction ( @ % ) was also similar between arms at @ hours and @ months .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40206,\n",
            "target:RESULTS,\n",
            "text:\tSymptom severity was reduced and quality of life improved equally at @ and @ months in each treatment group .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40207,\n",
            "target:RESULTS,\n",
            "text:\tComplications were minor in both groups .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40208,\n",
            "target:CONCLUSION,\n",
            "text:\tUterine leiomyoma infarction at @ hours and @ months after treatment with SPVA or TAG microspheres was comparable when using near-stasis as a procedural endpoint with SPVA microspheres .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40209,\n",
            "target:CONCLUSION,\n",
            "text:\tSymptom relief was maintained for as long as @ months for both embolic agents .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40210,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40212,\n",
            "target:BACKGROUND,\n",
            "text:\tWhereas routine prophylaxis for venous thromboembolism ( VTE ) is frequently utilized in the West , Asian physicians employ it much less often , based on its recorded rarity amongst their patients .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40213,\n",
            "target:BACKGROUND,\n",
            "text:\tThis study was designed to examine the incidence of VTE and to determine the optimal method of thromboembolic prophylaxis following gastrectomy for cancer .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40214,\n",
            "target:METHODS,\n",
            "text:\tIn this prospective , randomized trial , patients were assigned to either an intermittent pneumatic compression ( IPC ) only or an IPC plus enoxaparin .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40215,\n",
            "target:METHODS,\n",
            "text:\tThe primary end point of this study was to determine the VTE incidence rate within @ days of surgery .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40216,\n",
            "target:METHODS,\n",
            "text:\tA history with physical examinations for VTE and a serum d-dimer test was scheduled on postoperative days ( POD ) @ , @ , @ , and @ .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40217,\n",
            "target:METHODS,\n",
            "text:\tDuplex ultrasonography ( DUS ) was performed as an objective test for deep vein thrombosis at POD @ .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40218,\n",
            "target:METHODS,\n",
            "text:\tAn interim analysis was performed to determine if it was ethical to continue the study .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40219,\n",
            "target:METHODS,\n",
            "text:\tThis clinical trial was registered at www.clinicaltrials.gov ( NCT@ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40220,\n",
            "target:RESULTS,\n",
            "text:\tAmong the @ patients , @ ( all from the IPC group ) were diagnosed with VTE ; these cases were asymptomatic , having been detected only on DUS @ days after surgery .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40221,\n",
            "target:RESULTS,\n",
            "text:\tPostoperative bleeding occurred in @ cases , among which @ patients were in the IPC plus enoxaparin group .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40222,\n",
            "target:CONCLUSION,\n",
            "text:\tThis interim analysis showed a higher incidence of VTE in the IPC group but a higher bleeding rate in the IPC plus enoxaparin group .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40223,\n",
            "target:CONCLUSION,\n",
            "text:\tWe expect that this study , once completed , will provide information key to the determination of the optimal method for preventing VTE in Korean gastric cancer patients .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40224,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40226,\n",
            "target:BACKGROUND,\n",
            "text:\tA number of trials have shown improved radiological alignment following total knee arthroplasty using computer-assisted surgery ( CAS ) compared with conventional surgery .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40227,\n",
            "target:BACKGROUND,\n",
            "text:\tFew studies , however , have looked at functional outcomes .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40228,\n",
            "target:METHODS,\n",
            "text:\tWe prospectively studied a cohort of @ patients that underwent TKA by a single surgeon .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40229,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomised into @ groups : computer-assisted surgery for both the femur and the tibia , intramedullary guides for both the femur and the tibia , and an intramedullary guide for the femur and an extramedullary guide for the tibia .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40230,\n",
            "target:METHODS,\n",
            "text:\tPatients were followed-up post-operatively with the Short Form Health Survey ( SF-@ ) and Oxford Knee Score ( OKS ) questionnaires .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40231,\n",
            "target:RESULTS,\n",
            "text:\tAt a median follow-up of @ months ( range @-@ months ) , there was a trend towards higher OKS results in the CAS group , with a mean score of @ in the CAS group compared to @ in the extramedullary group and @ in the intramedullary group .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40232,\n",
            "target:RESULTS,\n",
            "text:\tThe difference seen in the OKS between CAS and the conventional groups had a significant unadjusted p-value ( @ ) , and approached significance when adjusted for age and sex ( @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40233,\n",
            "target:RESULTS,\n",
            "text:\tThere was a significant improvement in the OKS when the mechanical axis was within @ of neutral , versus those outside this range ( median of @ compared to @ , p = @ ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40234,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study shows that clinically significant differences are being seen in functional scores of patients treated with CAS versus conventional guides , at medium-term follow up .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40235,\n",
            "target:CONCLUSION,\n",
            "text:\tOur findings reinforce the tenet that a coronal mechanical axis of within @ of neutral equates to significantly better functional outcomes .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40236,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40238,\n",
            "target:BACKGROUND,\n",
            "text:\tWe aimed to compare patient-controlled thoracic or lumbar epidural analgesia methods after thoracotomy operations .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40239,\n",
            "target:METHODS,\n",
            "text:\tOne hundred and twenty patients were prospectively randomized to receive either thoracic epidural analgesia ( TEA group ) or lumbar epidural analgesia ( LEA group ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40240,\n",
            "target:METHODS,\n",
            "text:\tIn both groups , epidural catheters were administered .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40241,\n",
            "target:METHODS,\n",
            "text:\tHemodynamic measurements , visual analog scale scores at rest ( VAS-R ) and after coughing ( VAS-C ) , analgesic consumption , and side effects were compared at @ , @ , @ , @ , @ , and @ hours postoperatively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40242,\n",
            "target:RESULTS,\n",
            "text:\tThe VAS-R and VAS-C values were lower in the TEA group in comparison to the LEA group at @ , @ , @ , and @ hours after surgery ( for VAS-R , P = @ , P = @ , P = @ , and P = @ , respectively ; and for VAS-C , P = @ , P = @ , P = @ , and P = @ , respectively ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40243,\n",
            "target:RESULTS,\n",
            "text:\tTotal @-hour analgesic consumption was different between groups ( @ + / - @ mL versus @ + / - @ mL ; P = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40244,\n",
            "target:RESULTS,\n",
            "text:\tThe comparison of postoperative complications revealed that the incidence of hypotension ( @/@ , @ % versus @/@ , @ % ; P = @ ) , bradycardia ( @/@ , @ % versus @/@ , @ % ; P = @ ) , atelectasis ( @/@ , @ % versus @/@ , @ % ; P = @ ) , and the need for intensive care unit ( ICU ) treatment ( @/@ , @ % versus @/@ , @ % ; P = @ ) were lower in the TEA group in comparison to the LEA group .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40245,\n",
            "target:CONCLUSION,\n",
            "text:\tTEA has beneficial hemostatic effects in comparison to LEA after thoracotomies along with more satisfactory pain relief profile .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40246,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40248,\n",
            "target:BACKGROUND,\n",
            "text:\tGemifloxacin is a synthetic fluoroquinolone antimicrobial agent , which has potent activity against most Gram-negative and Gram-positive organisms .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40249,\n",
            "target:BACKGROUND,\n",
            "text:\tIt is indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40250,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe aim of this study was to assess the clinical potential of a new gemifloxacin @ mg intravenous formulation by comparing its pharmacokinetic characteristics with those of the branded Factive ( ) gemifloxacin tablet .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40251,\n",
            "target:METHODS,\n",
            "text:\tA single-dose , open-label , randomized-sequence , two-period crossover study was performed with @ healthy male volunteers .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40252,\n",
            "target:METHODS,\n",
            "text:\tThe two treatment periods were separated by a @-week washout period .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40253,\n",
            "target:METHODS,\n",
            "text:\tBlood samples were taken for up to @ h post-dose .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40254,\n",
            "target:METHODS,\n",
            "text:\tPlasma gemifloxacin concentrations were determined by a validated high-performance liquid chromatography-tandem mass spectrometry method .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40255,\n",
            "target:METHODS,\n",
            "text:\tTo calculate the pharmacokinetic parameters , noncompartmental analysis was performed .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40256,\n",
            "target:METHODS,\n",
            "text:\tThe two formulations were considered to be pharmacokinetically equivalent if the @ % confidence intervals ( CIs ) of the log-transformed ratios ( intravenous/oral formulations ) of the area under the plasma concentration-time curve ( AUC ) from time zero to the time of the last measurable concentration ( AUClast ) and the AUC from time zero to infinity ( AUC ) were within the standard bioequivalence range ( @-@ @ ) .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40257,\n",
            "target:METHODS,\n",
            "text:\tSafety and tolerability were evaluated on the basis of physical examinations , vital signs , electrocardiograms , clinical laboratory tests and adverse event monitoring .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40258,\n",
            "target:RESULTS,\n",
            "text:\tSeventeen subjects were enrolled , and @ subjects completed the study .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40259,\n",
            "target:RESULTS,\n",
            "text:\tSixteen subjects received intravenous @ mg gemifloxacin and @ received oral @ mg gemifloxacin .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40260,\n",
            "target:RESULTS,\n",
            "text:\tThe @ subjects in the pharmacokinetic analysis set had a mean ( standard deviation -LSB- SD -RSB- ) age , height and weight of @ ( @ ) years , @ ( @ ) cm and @ ( @ ) kg , respectively .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40261,\n",
            "target:RESULTS,\n",
            "text:\tBoth formulations had similar pharmacokinetic profiles .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40262,\n",
            "target:RESULTS,\n",
            "text:\tFor the intravenous formulation , the mean ( SD ) AUClast , AUC and maximum plasma concentration ( C max ) values were @ ( @ ) gh/mL , @ ( @ ) gh/mL and @ ( @ ) g/mL , respectively , while these values for the oral formulation were @ ( @ ) gh/mL , @ ( @ ) gh/mL and @ ( @ ) g/mL , respectively .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40263,\n",
            "target:RESULTS,\n",
            "text:\tFor the intravenous and oral formulations , the median ( range ) time to reach C max ( t max ) values were @ ( @-@ @ ) and @ ( @-@ @ ) h , respectively .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40264,\n",
            "target:RESULTS,\n",
            "text:\tThe mean relative bioavailability was @ % .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40265,\n",
            "target:RESULTS,\n",
            "text:\tThe @ % CI of the ratios of the log-transformed values of AUClast and AUC was @-@ @ .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40266,\n",
            "target:RESULTS,\n",
            "text:\tThere were no serious adverse events .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40267,\n",
            "target:RESULTS,\n",
            "text:\tThe intravenous and oral formulations were associated with treatment-emergent adverse event incidences of @ % ( @/@ ) and @ % ( @/@ ) , respectively .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40268,\n",
            "target:RESULTS,\n",
            "text:\tAfter the intravenous formulation was administered , application site pain and paraesthesia were the most frequently reported adverse events ( @ and @ % , respectively ) .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40269,\n",
            "target:RESULTS,\n",
            "text:\tAll adverse events resolved spontaneously without treatment .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40270,\n",
            "target:CONCLUSION,\n",
            "text:\tIntravenous @ mg and oral @ mg formulations of gemifloxacin are equivalent in terms of AUC following a single dose in healthy male subjects .,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40271,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:24]\n",
            "\n",
            "\n",
            "[line_number:40273,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo explore the changes of goiter prevalence of children living in areas with high iodine in drinking water after removing iodized salt from their diet .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40274,\n",
            "target:METHODS,\n",
            "text:\tThree towns with median water iodine of @ - @ g/L were selected randomly in Hengshui city of Hebei province of China .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40275,\n",
            "target:METHODS,\n",
            "text:\tA total of @ and @ children in the @ towns were randomly selected to measure thyroid volume by ultrasound before and after removing iodized salt , respectively .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40276,\n",
            "target:METHODS,\n",
            "text:\tTheir goiter status was judged using the criteria of age-specific thyroid volume recommended by the WHO .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40277,\n",
            "target:RESULTS,\n",
            "text:\tAfter removing iodized salt , the overall goiter prevalence in the three towns significantly decreased from @ % ( @/@ ) to @ % ( @/@ ) ( P < @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40278,\n",
            "target:RESULTS,\n",
            "text:\tThe goiter prevalence in @ , @ and @ year-old children decreased respectively from @ % ( @/@ ) , @ % ( @/@ ) and @ % ( @/@ ) to @ % ( @/@ ) , @ % ( @/@ ) and @ % ( @/@ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40279,\n",
            "target:RESULTS,\n",
            "text:\tThe goiter prevalence in boys and girls decreased from @ % ( @/@ ) and @ % ( @/@ ) to @ % ( @/@ ) and @ % ( @/@ ) , respectively .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40280,\n",
            "target:RESULTS,\n",
            "text:\tThe decreases in children 's goiter prevalence across gender and age group were all significant .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40281,\n",
            "target:CONCLUSION,\n",
            "text:\tChildren 's goiter prevalence decreased significantly after removing iodized salt from their diet for about one and half years in the HIA in Hebei province .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40282,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40284,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo observe the clinical effect and safety of Sulfasalazine ( SASP ) combined with ZHUANG medicine mediated thread moxibustion ( ZMMTM ) for patients with mild and moderate ulcerative colitis ( UC ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40285,\n",
            "target:METHODS,\n",
            "text:\tA total of @ UC patients were randomly and equally divided into moxibustion group ( SASP combined with ZMMTM ) and SASP medication group .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40286,\n",
            "target:METHODS,\n",
            "text:\tPatients of both groups were treated by oral administration of SASP ( @ g , tid ) for six weeks .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40287,\n",
            "target:METHODS,\n",
            "text:\tFor patients of the moxibustion group , ZMMTM was applied to points Tianshu ( ST @ ) , Qihai ( CV @ ) , Guanyuan ( CV @ ) , and Dachangshu ( BL @ ) , once a day , for @ times .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40288,\n",
            "target:METHODS,\n",
            "text:\tThe therapeutic effect was assessed according to Schroeder and colleagues ' method ( @ ) , scores of Baron ' s endoscope scale ( @ - @ scoring standards , @ ) , @ - @ scoring standards of activity indexes ( including @ items of diarrhea , hemorrhage , mucosal appearance and doctors ' evaluation ) , respectively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40289,\n",
            "target:RESULTS,\n",
            "text:\tOf the two @ UC patients in the medication and moxibustion groups , @ and @ had a complete remission in their symptoms , @ and @ experienced a remarkable improvement , @ and @ were effective , and @ and @ was invalid , with the effective rates being @ % and @ % , respectively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40290,\n",
            "target:RESULTS,\n",
            "text:\tFollowing the treatment , both endoscopic score and activity index in the moxibustion group were significantly lower than those of the medication group ( P < @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40291,\n",
            "target:CONCLUSION,\n",
            "text:\tZMMTM combined with medication is significantly superior to simple medication in relieving clinical symptoms of mild and moderate UC patients .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40292,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40294,\n",
            "target:OBJECTIVE,\n",
            "text:\tAny differences observed between natural glucagon-like peptide-@ ( GLP-@ ) and studies obtained with analogues might call for renewed considerations concerning the use and design of such analogues .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40295,\n",
            "target:OBJECTIVE,\n",
            "text:\tThus , we aimed to evaluate the dose-response relationship of recombinant glucagon-like peptide-@ ( @-@ ) amide ( rGLP-@ ) administered by continuous subcutaneous infusion ( CSCI ) in subjects with type @ diabetes .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40296,\n",
            "target:METHODS,\n",
            "text:\tWe compared the efficacy and safety of three doses of recombinant GLP-@ , ranging from @ to @ pmol/kg/min ( pkm ) and placebo , given by continuous subcutaneous infusion over @months in combination with metformin and sulphonylurea ( SU ) , to lower haemoglobin A@c ( HbA@c ) , fasting plasma glucose and weight in @ type @ diabetes patients with inadequate glycaemic control .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40297,\n",
            "target:RESULTS,\n",
            "text:\tThe mean decreases in HbA@c at endpoint ( week @ ) were significantly greater for all three rGLP-@ dose groups when each was compared with the placebo group , with the greatest decrease occurring in the @ pkm dose group ( -@ % , s.d. @ , p < @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40298,\n",
            "target:RESULTS,\n",
            "text:\tThe mean decreases in fasting plasma glucose from baseline to endpoint were significantly greater for all three rGLP-@ dose groups than for the placebo group , with the greatest decrease occurring in the @ pkm dose group ( -@ mg/dl , s.d. @ , p = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40299,\n",
            "target:RESULTS,\n",
            "text:\tBody weight was significantly reduced by @ kg ( s.d. @ ) in the @ pkm dose group only ( p = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40300,\n",
            "target:CONCLUSION,\n",
            "text:\tAdministration of rGLP-@ by CSCI over a @-week period in combination with metformin and an SU had a dose dependent effect in lowering HbA@c and fasting plasma glucose .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40301,\n",
            "target:CONCLUSION,\n",
            "text:\tHowever , administration of rGLP-@ by CSCI may be less effective with respect to lowering of body weight compared with the daily and once weekly analogues .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40302,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40304,\n",
            "target:BACKGROUND,\n",
            "text:\tBMS-@ , a novel triple monoamine reuptake inhibitor , is an experimental monotherapy for sufferers of major depressive disorder who have had an inadequate response to an existing antidepressant treatment .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40305,\n",
            "target:OBJECTIVE,\n",
            "text:\tThis study was conducted to evaluate the safety and tolerability , pharmacokinetics ( PK ) , and serotonin transporter ( SERT ) and dopamine transporter ( DAT ) occupancy for single doses of BMS-@ in healthy subjects .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40306,\n",
            "target:METHODS,\n",
            "text:\tHealthy subjects were assigned to seven BMS-@ dose panels ( @ , @ , @ , @ , @ , @ , and @ mg ; n = @ each ) , in which subjects were randomly allocated @:@ to a single BMS-@ dose or matched placebo .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40307,\n",
            "target:METHODS,\n",
            "text:\tSerial blood samples were collected on Days @ , @ , @ , @ , @ , and @ to characterize the PK of BMS-@ .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40308,\n",
            "target:METHODS,\n",
            "text:\tFollowing evaluation of the maximum tolerated dose , SERT occupancy was determined by applying -LSB- ( @ ) C -RSB- DASB positron emission tomography ( PET ) after single-dose BMS-@ ( @ or @ mg ; n = @ each ) and DAT occupancy by applying -LSB- ( @ ) C -RSB- PE@I PET after single-dose BMS-@ ( @ mg ; n = @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40309,\n",
            "target:RESULTS,\n",
            "text:\tSingle oral doses of BMS-@ ( @-@ mg ) were generally safe and well tolerated .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40310,\n",
            "target:RESULTS,\n",
            "text:\tBMS-@ had a median T max of @-@ @ h and a mean apparent terminal T @/@ of @-@ h. Mean striatal SERT occupancies were @ @ % and @ @ % after single doses of @ and @ mg BMS-@ , respectively .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40311,\n",
            "target:RESULTS,\n",
            "text:\tThe mean striatal DAT occupancy was @ @ % after a single @ mg BMS-@ dose .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40312,\n",
            "target:CONCLUSION,\n",
            "text:\tSingle doses of BMS-@ have meaningful SERT and DAT occupancy and demonstrate an acceptable safety and tolerability profile in healthy control subjects .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40313,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40315,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo evaluate the safety and efficacy of the novel tenofovir prodrug , tenofovir alafenamide ( TAF ) , as part of a single-tablet regimen ( STR ) for the initial treatment of HIV-@ infection .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40316,\n",
            "target:METHODS,\n",
            "text:\tPhase @ , randomized , double-blind , double-dummy , multicenter , active-controlled study .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40317,\n",
            "target:METHODS,\n",
            "text:\tAntiretroviral naive adults with HIV-@ RNA @ copies per milliliter and a CD@ count @ cells per microliter were randomized @:@ to receive an STR of elvitegravir/cobicistat/emtricitabine / tenofovir alafenamide ( E/C/F / TAF ) or elvitegravir/cobicistat/emtricitabine / tenofovir disoproxil fumarate ( E/C/F / TDF ) , plus placebo for @ weeks .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40318,\n",
            "target:RESULTS,\n",
            "text:\tPatients on both E/C/F / TAF ( n = @ ) and E/C/F / TDF ( n = @ ) had high rates of virologic suppression ( < @ HIV copies per milliliter ) at week @ ( @ % ; @ % ) and at week @ ( @ % ; @ % ) , and had similar improvements in CD@ at week @ ( @ ; @ ) , respectively .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40319,\n",
            "target:RESULTS,\n",
            "text:\tBoth treatments were well tolerated , and most adverse events were self-limiting and of mild to moderate severity .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40320,\n",
            "target:RESULTS,\n",
            "text:\tCompared with patients on E/C/F / TDF , patients on E/C/F / TAF had smaller reductions in estimated creatinine clearance ( -@ vs. -@ mL/min , P = @ ) , significantly less renal tubular proteinuria , and smaller changes in bone mineral density for hip ( -@ % vs. -@ % , P < @ ) and spine ( -@ % vs. -@ % , P < @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40321,\n",
            "target:RESULTS,\n",
            "text:\tPatients on E/C/F / TAF had higher increases in total cholesterol , low-density lipoprotein , and high-density lipoprotein , but the total cholesterol/high-density lipoprotein ratio was unchanged for both .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40322,\n",
            "target:CONCLUSION,\n",
            "text:\tTreatment-naive patients given the STR that contained either TAF or TDF achieved a high rate of virologic success .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40323,\n",
            "target:CONCLUSION,\n",
            "text:\tCompared with those receiving TDF , patients on E/C/F / TAF experienced significantly smaller changes in estimated creatinine clearance , renal tubular proteinuria , and bone mineral density .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40324,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40326,\n",
            "target:BACKGROUND,\n",
            "text:\tLarge-scale clinical trials have shown that routine monitoring of the platelet function in patients after percutanous coronary intervention ( PCI ) is not necessary .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40327,\n",
            "target:BACKGROUND,\n",
            "text:\tHowever , it is still unclear whether patients received high-risk PCI would benefit from a therapy which is guided by a selective platelet function monitoring .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40328,\n",
            "target:BACKGROUND,\n",
            "text:\tThis explanatory study sought to assess the benefit of a therapy guided by platelet function monitoring for these patients .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40329,\n",
            "target:METHODS,\n",
            "text:\tAcute coronary syndrome ( ACS ) patients ( n = @ ) who received high-risk , complex PCI were randomized into two groups .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40330,\n",
            "target:METHODS,\n",
            "text:\tPCI in the two types of lesions described below was defined as high-risk , complex PCI : lesions that could result in severe clinical outcomes if stent thrombosis occurred or lesions at high risk for stent thrombosis .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40331,\n",
            "target:METHODS,\n",
            "text:\tThe patients in the conventionally treated group received standard dual antiplatelet therapy .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40332,\n",
            "target:METHODS,\n",
            "text:\tThe patients in the platelet function monitoring guided group received an antiplated therapy guided by a modified thromboelastography ( TEG ) platelet mapping : If inhibition of platelet aggregation ( IPA ) induced by arachidonic acid ( AA ) was less than @ % the aspirin dosage was raised to @ mg/d ; if IPA induced by adenosine diphosphate ( ADP ) was less than @ % the clopidogrel dosage was raised to @ mg/d , for three months .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40333,\n",
            "target:METHODS,\n",
            "text:\tThe primary efficacy endpoint was a composite of myocardial infarction , emergency target vessel revascularization ( eTVR ) , stent thrombosis , and death in six months .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40334,\n",
            "target:RESULTS,\n",
            "text:\tThis study included @ patients ; @ and @ in the conventionally treated group and platelet function monitoring guided group , respectively .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40335,\n",
            "target:RESULTS,\n",
            "text:\tNo significant differences were observed in the baseline clinical characteristics and interventional data between the two groups .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40336,\n",
            "target:RESULTS,\n",
            "text:\tIn the platelet function monitoring guided group , the mean IPA induced by AA and ADP were ( @ @ ) % ( range , @ % to @ % ) and ( @ @ ) % ( range , @ % to @ % ) , respectively .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40337,\n",
            "target:RESULTS,\n",
            "text:\tThe AA-induced IPA of forty-three ( @ % ) patients was less than @ % and the ADP-induced IPA of fifty-seven ( @ % ) patients was less than @ % ; therefore , their drug dosages were adjusted .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40338,\n",
            "target:RESULTS,\n",
            "text:\tThe TEG was rechecked one to four weeks after PCI , and the results indicated that the IPAs had significantly improved ( P < @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40339,\n",
            "target:RESULTS,\n",
            "text:\tHowever , no significant differences were found in the rates of the primary efficacy endpoint .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40340,\n",
            "target:RESULTS,\n",
            "text:\tRates in the conventionally treated group and platelet function monitoring guided group were @ % and @ % , respectively ( hazard ratio : @ ; P = @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40341,\n",
            "target:CONCLUSION,\n",
            "text:\tAn antiplatelet therapy guided by TEG monitored platelet function could not improve clinical efficacy even in ACS patients treated with high-risk complex PCI .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40342,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40344,\n",
            "target:BACKGROUND,\n",
            "text:\tThis study was conducted to determine the effect of oral midazolam ( OM ) or intranasal dexmedetomidine ( IND ) on the EC@ of sevoflurane for successful laryngeal mask airway placement in children .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40345,\n",
            "target:BACKGROUND,\n",
            "text:\tWe hypothesize that premedication with either agent might reduce the sevoflurane EC@ for laryngeal mask airway placement in children to a similar extent .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40346,\n",
            "target:METHODS,\n",
            "text:\tFifty-two American Society of Anesthesiologists ( ASA ) I children ( aged @-@ years ) scheduled for general anesthesia with laryngeal mask airway were randomized to one of the three groups : group M received @ mg kg ( -@ ) OM with honey and intranasal saline , group D received @ g kg ( -@ ) IND along with oral honey , and group P received oral honey and intranasal saline at least @ min prior to induction of anesthesia .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40347,\n",
            "target:METHODS,\n",
            "text:\tAnesthesia was induced with incremental sevoflurane up to @ % in @ % O@ .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40348,\n",
            "target:METHODS,\n",
            "text:\tA predetermined target endtidal sevoflurane ( ETsevo ) concentration ( @ % in the first child of all three groups ) was sustained for @ min before the attempt of laryngeal mask airway insertion by adjusting dial concentration .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40349,\n",
            "target:METHODS,\n",
            "text:\tNo intravenous anesthetic or neuromuscular blockade was used .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40350,\n",
            "target:METHODS,\n",
            "text:\tETsevo was increased/decreased ( step size @ % ) using Dixon 's and Massey 's up and down method in next patient depending upon previous patient 's response .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40351,\n",
            "target:METHODS,\n",
            "text:\tPlacement of the laryngeal mask airway without movement , coughing , biting , or bucking was considered as successful .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40352,\n",
            "target:METHODS,\n",
            "text:\tEC@ of sevoflurane was calculated as the average of the crossover midpoints in each group , which was further confirmed by probit analysis .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40353,\n",
            "target:RESULTS,\n",
            "text:\tThe EC@ of sevoflurane for laryngeal mask airway placement after OM ( @ @ ) and IND ( @ @ ) premedications was significantly lower than the placebo group ( @ @ , P < @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40354,\n",
            "target:RESULTS,\n",
            "text:\tThe EC@ ( @ % CI ) derived from probit regression analysis was @ % ( @-@ @ % ) with OM , @ % ( @-@ @ % ) with IND , and @ % ( @-@ @ % ) with placebo group .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40355,\n",
            "target:CONCLUSION,\n",
            "text:\tOral midazolam and IND premedications significantly reduce the sevoflurane EC@ for laryngeal mask airway insertion in children by @ % and @ % , respectively .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40356,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40358,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo evaluate the safety of different doses of subconjunctival bevacizumab and their effects on the recurrence rate after primary pterygium excision .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40359,\n",
            "target:METHODS,\n",
            "text:\tThis prospective randomized placebo-controlled clinical study was conducted on @ eyes ( @ patients ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40360,\n",
            "target:METHODS,\n",
            "text:\tThe visual acuity , refractive astigmatism , horizontal length of the pterygium , and recurrence risk factors were recorded .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40361,\n",
            "target:METHODS,\n",
            "text:\tThere were no statistically significant differences between the groups for age , sex , horizontal length of pterygium , preoperative visual acuity , astigmatism , and recurrence risk factors .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40362,\n",
            "target:METHODS,\n",
            "text:\tThe pterygium was excised from the conjunctival side and then peeled off the cornea .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40363,\n",
            "target:METHODS,\n",
            "text:\tThe bare sclera was covered with a rotational conjunctival flap from the superonasal area .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40364,\n",
            "target:METHODS,\n",
            "text:\tAfter surgery , Group @ ( @ patients ) , Group @ ( @ patients ) and Group @ ( @ patients ) received @ mg bevacizumab , @ mg bevacizumab , and Balanced Salt Solution ( BSS ) subconjunctivally , respectively .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40365,\n",
            "target:METHODS,\n",
            "text:\tPostoperatively , horizontal length of corneal epithelial defect , conjunctival congestion , and lacrimation were checked on the first and seventh day .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40366,\n",
            "target:METHODS,\n",
            "text:\tThe rate of recurrence ( > @ mm fibrovascular overgrowth on the cornea ) at month @ was compared between the groups .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40367,\n",
            "target:RESULTS,\n",
            "text:\tThere were no statistically significant differences between the groups for all measured variables except for moderate conjunctival congestion on the first postoperative day which was more common in the bevacizumab groups ( P = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40368,\n",
            "target:RESULTS,\n",
            "text:\tFour eyes in Groups @ ( @ % ) and @ ( @ % ) and @ in Group @ ( @ % ) experienced recurrence ( p = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40369,\n",
            "target:RESULTS,\n",
            "text:\tAll recurrences occurred at month @ and subsequently thereafter .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40370,\n",
            "target:CONCLUSION,\n",
            "text:\tIn our study , perioperative injections of subconjunctival bevacizumab had no effect on primary pterygium recurrence and were not associated with any specific local complications .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40371,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40373,\n",
            "target:BACKGROUND,\n",
            "text:\tAlthough many malaria control programmes in sub-Saharan Africa use indoor residual spraying with long-lasting insecticidal nets ( LLINs ) , the two studies assessing the benefit of the combination of these two interventions gave conflicting results .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40374,\n",
            "target:BACKGROUND,\n",
            "text:\tWe aimed to assess whether the addition of indoor residual spraying to LLINs provided a significantly different level of protection against clinical malaria in children or against house entry by vector mosquitoes .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40375,\n",
            "target:METHODS,\n",
            "text:\tIn this two-arm cluster , randomised , controlled efficacy trial we randomly allocated clusters of Gambian villages using a computerised algorithm to LLINs alone ( n = @ ) or indoor residual spraying with dichlorodiphenyltrichloroethane plus LLINs ( n = @ ) .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40376,\n",
            "target:METHODS,\n",
            "text:\tIn each cluster , @-@ children , aged @ months to @ years , were surveyed at the start of the @ transmission season and followed in @ and @ by passive case detection for clinical malaria .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40377,\n",
            "target:METHODS,\n",
            "text:\tExposure to parasite transmission was assessed by collection of vector mosquitoes with both light and exit traps indoors .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40378,\n",
            "target:METHODS,\n",
            "text:\tPrimary endpoints were the incidence of clinical malaria assessed by passive case detection and number of Anopheles gambiae sensu lato mosquitoes collected per light trap per night .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40379,\n",
            "target:METHODS,\n",
            "text:\tIntervention teams had no role in data collection and the data collection teams were not informed of the spray status of villages .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40380,\n",
            "target:METHODS,\n",
            "text:\tThe trial is registered at the ISRCTN registry , number ISRCTN@ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40381,\n",
            "target:RESULTS,\n",
            "text:\tLLIN coverage in @ was @ ( @ % ) of @ children in the indoor residual spraying plus LLIN group and @ ( @ % ) of @ in the LLIN group .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40382,\n",
            "target:RESULTS,\n",
            "text:\tIn @ , @ children were enrolled , @ completed passive case detection , and @ ( @ % ) had complete clinical and covariate data .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40383,\n",
            "target:RESULTS,\n",
            "text:\tIn @ , @ children remained in the study , @ more were enrolled , @ completed passive case detection , and @ ( @ % ) had complete data .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40384,\n",
            "target:RESULTS,\n",
            "text:\tIndoor residual spraying coverage per cluster was more than @ % for both years in the indoor residual spraying plus LLIN group .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40385,\n",
            "target:RESULTS,\n",
            "text:\tIncidence of clinical malaria was @ per child-month at risk in the LLIN group and @ per child-month at risk in the indoor residual spraying plus LLIN group in @ , and @ per child-month at risk in the LLIN group and @ per child-month at risk in the indoor residual spraying plus LLIN group in @ .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40386,\n",
            "target:RESULTS,\n",
            "text:\tThe incident rate ratio was @ ( @ % CI @-@ @ ) controlling for confounders and cluster by mixed-effect negative binomial regression on all malaria attacks for both years .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40387,\n",
            "target:RESULTS,\n",
            "text:\tNo significant difference was recorded in the density of vector mosquitoes caught in light traps in houses over the two transmission seasons ; the mean number of A gambiae sensu lato mosquitoes per trap per night was @ ( @-@ @ ) in the LLIN group and @ ( @-@ @ ) in the indoor residual spraying plus LLIN group ( p = @ in the random-effects linear regression model ) .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40388,\n",
            "target:CONCLUSION,\n",
            "text:\tWe identified no significant difference in clinical malaria or vector density between study groups .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40389,\n",
            "target:CONCLUSION,\n",
            "text:\tIn this area with high LLIN coverage , moderate seasonal transmission , and susceptible vectors , indoor residual spraying did not provide additional benefit .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40390,\n",
            "target:BACKGROUND,\n",
            "text:\tUK Medical Research Council .,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40391,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:19]\n",
            "\n",
            "\n",
            "[line_number:40393,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe purpose of the study was to examine changes in quality of life measures in patients who have undergone an intensive exercise program following a single level microdiskectomy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40394,\n",
            "target:METHODS,\n",
            "text:\tRandomized controlled trial with blinded examiners .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40395,\n",
            "target:METHODS,\n",
            "text:\tThe study was conducted in outpatient physical therapy clinics .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40396,\n",
            "target:METHODS,\n",
            "text:\tNinety-eight participants ( @ male , @ female ) who had undergone a single-level lumbar microdiskectomy allocated to receive exercise and education or education only .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40397,\n",
            "target:METHODS,\n",
            "text:\tA @-week periodized exercise program of lumbar extensor strength and endurance training , and mat and upright therapeutic exercises was administered .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40398,\n",
            "target:METHODS,\n",
            "text:\tQuality of life was tested with the Short Form @ ( SF-@ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40399,\n",
            "target:METHODS,\n",
            "text:\tMeasurements were taken @-@ weeks postsurgery and following completion of the @-week intervention program .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40400,\n",
            "target:METHODS,\n",
            "text:\tSince some participants selected physical therapy apart from the study , analyses were performed for both an as-randomized ( two-group ) design and an as-treated ( three-group ) design .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40401,\n",
            "target:RESULTS,\n",
            "text:\tIn the two-group analyses , exercise and education resulted in a greater increase in SF-@ scales , role physical ( @ vs. @ ) and bodily pain ( @ vs. @ ) , and the physical component summary ( @ vs. @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40402,\n",
            "target:RESULTS,\n",
            "text:\tIn the three-group analyses , post-hoc comparisons showed exercise and education resulted in a greater increase in the SF-@ scales , physical function ( @ vs. @ ) and bodily pain ( @ vs. @ ) , and the physical component summary ( @ vs. @ ) when compared with usual physical therapy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40403,\n",
            "target:CONCLUSION,\n",
            "text:\tAn intensive , progressive exercise program combined with education increases quality of life in patients who have recently undergone lumbar microdiskectomy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40404,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40406,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo analyze the impact of the eSET followed by single-embryo cryotransfer versus double embryo transfer in older women ( < @ years ) without taking into account embryo quality .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40407,\n",
            "target:METHODS,\n",
            "text:\tThis is a prospective randomised clinical trial performed on @ couples attempting a first IVF cycle in a Public Hospital in Spain .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40408,\n",
            "target:METHODS,\n",
            "text:\tThe women in Group @ received eSET plus a single-embryo cryotransfer , and those in Group @ received a double embryo transfer ( DET ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40409,\n",
            "target:RESULTS,\n",
            "text:\tIn the intention-to-treat analysis , the cumulative live birth delivery rate in the eSET group was similar to the results obtained for the DET group ( @ % vs. @ % ; p = @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40410,\n",
            "target:RESULTS,\n",
            "text:\tThe rate of multiple gestation was significantly lower in the eSET group than in the DET group ( @ % vs. @ % ; p < @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40411,\n",
            "target:RESULTS,\n",
            "text:\tThe findings obtained in the per-protocol analysis were similar to those obtained in the intention-to-treat analysis .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40412,\n",
            "target:RESULTS,\n",
            "text:\tThe per-protocol analysis revealed no significant differences in the rate of implantation ( @ % in eSET vs. @ % in DET ; p = @ ) , in cumulative pregnancy rates per transfer ( @ % in eSET vs. @ % in DET ; p = @ ) or in the cumulative live birth delivery rate ( @ % in eSET vs. @ % in DET ; p = @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40413,\n",
            "target:RESULTS,\n",
            "text:\tIn the cycles with eSET , there were no twin pregnancies ( @ % in eSET vs. @ in DET ; p < @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40414,\n",
            "target:CONCLUSION,\n",
            "text:\tFor women aged under @ years with good prognosis , without taking embryo quality as a criterion for inclusion , an eSET policy can be applied , achieving acceptable cumulative clinical pregnancy rates and birth rates .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40415,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40417,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo evaluate the effect of nursing intervention on the quality of life of patients with advanced schistosomiasis .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40418,\n",
            "target:METHODS,\n",
            "text:\tA total of @ cases of advanced schistosomiasis were randomly divided into a control group and an experimental group ( @ cases each ) .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40419,\n",
            "target:METHODS,\n",
            "text:\tThe patients in the control group received the conventional nursing , while the patients in the experimental group received the conventional nursing plus other interventions such as the health education , psychological counseling and diet guidance .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40420,\n",
            "target:METHODS,\n",
            "text:\tThe complications and scores of life quality of the patients in the @ groups were observed and compared .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40421,\n",
            "target:RESULTS,\n",
            "text:\tThe awareness of knowledge about the disease improved from @ % to @ % , the incidence of complications decreased from @ % to @ % , and the scores of life quality improved significantly in the experimental group , which were much better than those in the control group .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40422,\n",
            "target:CONCLUSION,\n",
            "text:\tThe nursing intervention on the quality of life of patients with advanced schistosomiasis is effective .,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40423,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:7]\n",
            "\n",
            "\n",
            "[line_number:40425,\n",
            "target:OBJECTIVE,\n",
            "text:\tMentorship within academic institutions influences research productivity ; no published studies have addressed whether encouragement on a national level would have similar effects .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40426,\n",
            "target:OBJECTIVE,\n",
            "text:\tWe studied whether contact by a journal 's editorial board members would affect submission rates or journal selection by authors .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40427,\n",
            "target:METHODS,\n",
            "text:\tAuthors of potentially publishable conference materials presented at national conferences sponsored by the Society of Teachers of Family Medicine were randomized to receive an invitation to submit work to Family Medicine or to receive no contact .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40428,\n",
            "target:METHODS,\n",
            "text:\tAfter @ years , we surveyed authors regarding whether a manuscript had been attempted and , if completed , where it had been submitted and eventually published .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40429,\n",
            "target:RESULTS,\n",
            "text:\tA total of @ submissions were reviewed , @ met inclusion criteria , and @ authors responded to the survey ( @ % ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40430,\n",
            "target:RESULTS,\n",
            "text:\tThere were no differences in demographics , scholarly activity in general , or faculty status between study groups .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40431,\n",
            "target:RESULTS,\n",
            "text:\tThere was no significant difference in whether manuscripts based on targeted projects had been written , completed , submitted , or published .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40432,\n",
            "target:RESULTS,\n",
            "text:\tThere was a significant difference in where manuscripts were submitted with the inviting journal receiving proportionately more submissions from the group of authors that had been contacted ( @ % Contacted group , @ % No-Contact ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40433,\n",
            "target:CONCLUSION,\n",
            "text:\tSimple encouragement from editorial board members of a national peer-reviewed journal in the form of a single e-mail invitation did not increase the scholarly production of authors .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40434,\n",
            "target:CONCLUSION,\n",
            "text:\tEncouragement may , however , increase the likelihood that completed works are submitted to the inviting journal , which is a useful finding for journals interested in soliciting scholarly works of interest .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40435,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40437,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe objective of this multicenter , randomized study was to investigate the efficacy of the hydrophilic resorbable film PREVADH in preventing postoperative adhesions following myomectomy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40438,\n",
            "target:METHODS,\n",
            "text:\tWomen scheduled for laparotomic myomectomy with intramural and/or subserous myomas of > @mm in diameter , and who wished to preserve fertility , were eligible .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40439,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomized immediately prior to abdominal wall closure to receive either hydrophilic resorbable film applied directly to the incisions ( P-Group , n = @ ) or @mL Ringer 's lactate solution instilled into the pelvic cavity ( R-Group , n = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40440,\n",
            "target:METHODS,\n",
            "text:\tIncidence , severity , and extent of postoperative adhesions to the uterine incisions and adnexal and abdominopelvic adhesions were assessed during second-look laparoscopy @-@ weeks after the initial surgery .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40441,\n",
            "target:METHODS,\n",
            "text:\tUnedited videotapes of this second-look procedure were reviewed by two blinded independent surgeons .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40442,\n",
            "target:RESULTS,\n",
            "text:\tFifty-four patients ( P-Group , n = @ ; R-Group , n = @ ) underwent second-look laparoscopy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40443,\n",
            "target:RESULTS,\n",
            "text:\tSignificantly fewer P-Group patients developed adhesions to uterine incisions than R-Group patients ( @ % vs. @ % , P = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40444,\n",
            "target:RESULTS,\n",
            "text:\tAdhesions , which were confirmed by independent reviewers , were found in significantly fewer P-Group sites than R-Group sites ( @ % vs. @ % , P = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40445,\n",
            "target:RESULTS,\n",
            "text:\tNo serious adverse events related to the barriers used or adhesion-related complications were reported in either group .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40446,\n",
            "target:CONCLUSION,\n",
            "text:\tThe hydrophilic resorbable anti-adhesion film PREVADH significantly reduced adhesion incidence and severity after laparotomic myomectomy .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40447,\n",
            "target:BACKGROUND,\n",
            "text:\tNCT@ ( www.clinicaltrials.gov ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40448,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40450,\n",
            "target:BACKGROUND,\n",
            "text:\tElevated plasma concentrations of liver function tests are prevalent in patients with chronic heart failure ( HF ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40451,\n",
            "target:BACKGROUND,\n",
            "text:\tLittle is known about liver function in patients with acute HF .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40452,\n",
            "target:BACKGROUND,\n",
            "text:\tWe aimed to assess the prevalence and prognostic value of serial measurements of liver function tests in patients admitted with acute decompensated HF .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40453,\n",
            "target:METHODS,\n",
            "text:\tWe investigated liver function tests from all @ patients from the Relaxin for the Treatment of Patients With Acute Heart Failure study at baseline and during hospitalization .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40454,\n",
            "target:METHODS,\n",
            "text:\tThe end points were worsening HF through day @ , @-day mortality or rehospitalization , and @-day mortality .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40455,\n",
            "target:RESULTS,\n",
            "text:\tMean age was @ @ years , @ % were male , and most patients were in New York Heart Association functional class III/IV ( @ % ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40456,\n",
            "target:RESULTS,\n",
            "text:\tAbnormal liver function tests were frequently found for alanine transaminase ( ALT ; @ % ) , aspartate transaminase ( AST ; @ % ) , alkaline phosphatase ( @ % ) , and total bilirubin ( @ % ) , and serum albumin ( @ % ) and total protein ( @ % ) were decreased .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40457,\n",
            "target:RESULTS,\n",
            "text:\tIn-hospital changes were very small .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40458,\n",
            "target:RESULTS,\n",
            "text:\tOn a continuous scale , baseline ALT and AST were associated with @-day mortality ( hazard ratios -LSB- HRs ; per doubling -RSB- @ -LSB- P = @ -RSB- and @ -LSB- P = @ -RSB- , respectively ) and worsening HF through day @ ( HRs -LSB- per doubling -RSB- @ -LSB- P = @ -RSB- and @ -LSB- P = @ -RSB- , respectively ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40459,\n",
            "target:RESULTS,\n",
            "text:\tAlbumin was associated with @-day mortality ( HR @ ; P = @ ) but not with worsening HF ( HR @ ; P = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40460,\n",
            "target:RESULTS,\n",
            "text:\tTotal protein was associated with only worsening HF ( HR @ ; P = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40461,\n",
            "target:CONCLUSION,\n",
            "text:\tAbnormal liver function tests are often present in patients with acute HF and are associated with an increased risk for mortality , rehospitalization , and in-hospital worsening HF .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40462,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40464,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo evaluate the effects of epinephrine ( @:@,@ ) in the epidural space on the incidence of blood vessel injury by epidural catheter insertion for cesarean section .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40465,\n",
            "target:METHODS,\n",
            "text:\tProspective observational study .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40466,\n",
            "target:METHODS,\n",
            "text:\tUniversity-affiliated teaching hospital .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40467,\n",
            "target:METHODS,\n",
            "text:\tFour hundred laboring women with singleton cephalic presentations at term who underwent cesarean section and requested continuous epidural analgesia .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40468,\n",
            "target:METHODS,\n",
            "text:\tPredistension of @ mL of isotonic sodium chloride solution containing epinephrine ( @:@,@ ) or @ mL of isotonic sodium chloride solution through an epidural needle before catheter insertion .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40469,\n",
            "target:METHODS,\n",
            "text:\tCases with bloody fluid in the epidural needle or catheter during catheter insertion , aspiration of frank blood from the epidural catheter , and blood noted in the caudal end of the epidural catheter upon removal were recorded .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40470,\n",
            "target:RESULTS,\n",
            "text:\tEight parturients were excluded from the analysis for technical reasons .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40471,\n",
            "target:RESULTS,\n",
            "text:\tThere were no significant differences between patients in the @ groups with respect to cases with bloody fluid in the epidural needle during catheter insertion ( @ % vs @ % , P = @ ) , the epidural catheter during catheter placement ( @ % vs @ % , P = @ ) , aspiration of frank blood in the epidural catheter ( @ % vs @ % , P = @ ) , and blood noted in the caudal end of the epidural catheter upon removal ( @ % vs @ % ; P > @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40472,\n",
            "target:CONCLUSION,\n",
            "text:\tTwenty-five micrograms of epinephrine ( @:@,@ ) in the epidural space does not reduce the incidence of blood vessel injury induced by insertion of an epidural catheter .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40473,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40475,\n",
            "target:BACKGROUND,\n",
            "text:\tThe incidence of vaccine-preventable disease is increasing .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40476,\n",
            "target:BACKGROUND,\n",
            "text:\tSeveral guidelines recommend annual influenza vaccination for patients with inflammatory bowel disease .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40477,\n",
            "target:METHODS,\n",
            "text:\tUsing the Business Objects database of Clalit Health Services in the Tel Aviv district we identified all patients older than @ years with a diagnosis of Crohn 's disease ( CD ) on December @ , @ .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40478,\n",
            "target:METHODS,\n",
            "text:\tThis cohort was followed until December @ , @ .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40479,\n",
            "target:METHODS,\n",
            "text:\tSubjects without inflammatory bowel disease older than @ years served as controls .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40480,\n",
            "target:METHODS,\n",
            "text:\tThe uptake of annual influenza vaccination was recorded .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40481,\n",
            "target:RESULTS,\n",
            "text:\tThe study included @ patients with CD ( @ -LSB- @ % -RSB- men , age @ @ years , disease duration @ @ months ) and @ controls ( @ -LSB- @ % -RSB- men , P < @ , age @ @ years , P < @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40482,\n",
            "target:RESULTS,\n",
            "text:\tThe mean number of influenza vaccines received from @ to @ was @ @ and @ @ in CD and controls , respectively ( P < @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40483,\n",
            "target:RESULTS,\n",
            "text:\tUptake was higher in patients with CD aged @ to @ years and @ to @ years , compared with controls ( @ @ versus @ @ , P < @ and @ @ versus @ @ , P = @ , respectively ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40484,\n",
            "target:RESULTS,\n",
            "text:\tVaccination uptake increased significantly over time in both groups ( P < @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40485,\n",
            "target:RESULTS,\n",
            "text:\tPredictors of vaccination in CD included age , female sex , immunosuppression , and cardiovascular disease .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40486,\n",
            "target:CONCLUSION,\n",
            "text:\tUptake of influenza vaccination in CD has increased over the past @ years , and among subjects older than @ years , uptake remains higher in age-matched controls .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40487,\n",
            "target:CONCLUSION,\n",
            "text:\tNevertheless , overall uptake remains low , particularly in young males .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40488,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40490,\n",
            "target:BACKGROUND,\n",
            "text:\tEnvironmental enteric dysfunction ( EED ) is an acquired syndrome of impaired gastrointestinal mucosal barrier function that is thought to play a key role in the pathogenesis of stunting in early life .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40491,\n",
            "target:BACKGROUND,\n",
            "text:\tIt has been conceptualized as an adaptive response to excess environmental pathogen exposure .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40492,\n",
            "target:BACKGROUND,\n",
            "text:\tHowever , it is clinically similar to other inflammatory enteropathies , which result from both host and environmental triggers , and for which immunomodulation is a cornerstone of therapy .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40493,\n",
            "target:METHODS,\n",
            "text:\tIn this pilot double-blind randomized placebo-controlled trial , @ children with severe acute malnutrition and evidence of EED were assigned to treatment with mesalazine or placebo for @ days during nutritional rehabilitation .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40494,\n",
            "target:METHODS,\n",
            "text:\tPrimary outcomes were safety and acceptability of the intervention .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40495,\n",
            "target:RESULTS,\n",
            "text:\tTreatment with mesalazine was safe : there was no excess of adverse events , evidence of deterioration in intestinal barrier integrity or impact on nutritional recovery .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40496,\n",
            "target:RESULTS,\n",
            "text:\tThere were modest reductions in several inflammatory markers with mesalazine compared to placebo .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40497,\n",
            "target:RESULTS,\n",
            "text:\tDepression of the growth hormone -- insulin-like growth factor-@ axis was evident at enrollment and associated with inflammatory activation .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40498,\n",
            "target:RESULTS,\n",
            "text:\tIncreases in the former and decreases in the latter correlated with linear growth .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40499,\n",
            "target:CONCLUSION,\n",
            "text:\tIntestinal inflammation in EED is non-essential for mucosal homeostasis and is at least partly maladaptive .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40500,\n",
            "target:CONCLUSION,\n",
            "text:\tFurther trials of gut-specific immunomodulatory therapies targeting host inflammatory activation in order to optimize the growth benefits of nutritional rehabilitation and to address stunting are warranted .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40501,\n",
            "target:CONCLUSION,\n",
            "text:\tFunded by The Wellcome Trust .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40502,\n",
            "target:BACKGROUND,\n",
            "text:\tRegistered at Clinicaltrials.gov NCT@ .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40503,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40505,\n",
            "target:BACKGROUND,\n",
            "text:\tAttenuating postreperfusion syndrome during orthotopic liver transplant is very important for transplant anesthesiologists because of the syndrome 's complications .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40506,\n",
            "target:OBJECTIVE,\n",
            "text:\tOxygen-derived free radicals play an important role in the genesis of postreperfusion syndrome , but the effect of mannitol ( a free radical scavenger ) on attenuating the syndrome is unclear.OBJECTIVES-To investigate the effectiveness of infusing mannitol during the anhepatic phase in preventing postreperfusion syndrome , as indicated by postreperfusion cardiac output and central venous oxygen saturation .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40507,\n",
            "target:METHODS,\n",
            "text:\tIn a randomized clinical trial , @ patients who had undergone orthotopic liver transplant were allocated to @ groups .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40508,\n",
            "target:METHODS,\n",
            "text:\tDuring the anhepatic phase , patients in the mannitol group received @g/kg mannitol , whereas those in the control group received physiological saline .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40509,\n",
            "target:METHODS,\n",
            "text:\tMean arterial pressure , cardiac output , and central venous oxygen saturation were measured before and after the portal vein was declamped .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40510,\n",
            "target:METHODS,\n",
            "text:\tSerum levels of sodium and potassium were recorded at baseline and after portal vein declamping.Setting-Shiraz Organ Transplant Center , Shiraz , Iran .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40511,\n",
            "target:RESULTS,\n",
            "text:\tIn the mannitol group , no significant change was found in mean arterial pressure , cardiac output , and central venous oxygen saturation before and after declamping of the portal vein ( P = @ , P = @ , and P = @ , respectively ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40512,\n",
            "target:RESULTS,\n",
            "text:\tHowever , after declamping in the control group , mean arterial pressure , cardiac output , and central venous oxygen saturation were significantly lower than before declamping ( P = @ , P = @ , and P < @ , respectively ) .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40513,\n",
            "target:RESULTS,\n",
            "text:\tNo significant change in serum levels of sodium and potassium from baseline to after declamping were found in either group .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40514,\n",
            "target:CONCLUSION,\n",
            "text:\tInfusion of mannitol @ g/kg during the anhepatic phase was effective in attenuating postreperfusion syndrome without stress about hyperkalemia or hyponatremia during anesthesia .,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40515,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:11]\n",
            "\n",
            "\n",
            "[line_number:40517,\n",
            "target:BACKGROUND,\n",
            "text:\tPrior studies have found that smokers with STEMI have lower mortality rates and a more favorable response to fibrinolytic therapy than nonsmokers , phenomenon defined as `` the smoker 's paradox '' .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40518,\n",
            "target:BACKGROUND,\n",
            "text:\tStill poorly explored is the impact of cigarette smoking in patients undergoing primary percutaneous coronary intervention .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40519,\n",
            "target:BACKGROUND,\n",
            "text:\tAim of the current study was to evaluate the impact of cigarette smoking on scintigraphic infarct size in STEMI patients undergoing primary PCI .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40520,\n",
            "target:METHODS,\n",
            "text:\tOur population is represented by @ STEMI patients undergoing primary PCI .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40521,\n",
            "target:METHODS,\n",
            "text:\tInfarct size was evaluated at @ days by technetium-@m-sestamibi .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40522,\n",
            "target:RESULTS,\n",
            "text:\tSmoking was associated with younger age ( p < @ ) , a lower prevalence of female gender ( p < @ ) , hypertension ( p < @ ) , diabetes ( p = @ ) , shorter ischemia time ( p = @ ) , but higher rates of previous PCI ( p = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40523,\n",
            "target:RESULTS,\n",
            "text:\tNo differences were observed in other clinical or angiographic characteristics .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40524,\n",
            "target:RESULTS,\n",
            "text:\tIn particular , smoking did not affect the rate of postprocedural TIMI @ flow .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40525,\n",
            "target:RESULTS,\n",
            "text:\tAs shown in Fig. @ , smoking did not affect infarct size ( @ % -LSB- @ % -@ % -RSB- vs @ % -LSB- @ % -@ % -RSB- , p = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40526,\n",
            "target:RESULTS,\n",
            "text:\tSimilar results were observed in subanalyses according to infarct location ( anterior STEMI , p int = @ ) , gender ( p int = @ ) age , ( p Int = @ ) , diabetes ( p int = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40527,\n",
            "target:RESULTS,\n",
            "text:\tThe absence of any impact of smoking on infarct size was confirmed after correction for baseline characteristics , such as age , gender , hypertension , diabetes , previous PCI , ischemia time ( OR -LSB- @ % CI -RSB- = @ -LSB- @-@ @ -RSB- , p = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40528,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study shows that among STEMI patients undergoing primary PCI smoking status does not affect infarct size .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40529,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40531,\n",
            "target:OBJECTIVE,\n",
            "text:\tContinuous intraoperative norepinephrine infusion combined with restrictive deferred hydration improves surgical field visibility , and significantly decreases intraoperative blood loss and postoperative complications in patients undergoing radical cystectomy and urinary diversion .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40532,\n",
            "target:OBJECTIVE,\n",
            "text:\tWe determined whether the intraoperative fluid regimen would affect functional results ( continence and erectile function ) @ year after orthotopic ileal bladder substitution .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40533,\n",
            "target:METHODS,\n",
            "text:\tWe analyzed a subgroup of @ patients who received an ileal orthotopic bladder substitute .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40534,\n",
            "target:METHODS,\n",
            "text:\tThe subgroup was part of a randomized trial in @ patients initially allocated to continuous norepinephrine administration starting with @ g/kg per hour combined with @ ml/kg per hour initially and @ ml/kg per hour crystalloid infusion after cystectomy ( norepinephrine/low volume group of @ ) or a standard crystalloid infusion of @ ml/kg per hour throughout surgery ( @ controls ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40535,\n",
            "target:METHODS,\n",
            "text:\tWe prospectively assessed daytime and nighttime continence , and erectile function @ year postoperatively in the @-patient subgroup .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40536,\n",
            "target:RESULTS,\n",
            "text:\tDaytime continence was reported by @ of @ patients ( @ % ) in the norepinephrine/low volume group and by @ of @ controls ( @ % ) ( p = @ ) , and nighttime continence was reported by @ ( @ % ) and @ ( @ % ) , respectively ( p = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40537,\n",
            "target:RESULTS,\n",
            "text:\tErectile function recovery was reported by @ of @ preoperatively potent patients ( @ % ) in the norepinephrine/low volume group and by @ of @ controls ( @ % ) ( p = @ ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40538,\n",
            "target:CONCLUSION,\n",
            "text:\tPatients who undergo radical cystectomy and orthotopic bladder substitution with continuous norepinephrine infusion and restrictive hydration during surgery have significantly better daytime continence and erectile function @ year postoperatively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40539,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40541,\n",
            "target:BACKGROUND,\n",
            "text:\tWomen with depression in pregnancy are faced with difficult treatment decisions .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40542,\n",
            "target:BACKGROUND,\n",
            "text:\tUntreated , antenatal depression has serious negative implications for mothers and children .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40543,\n",
            "target:BACKGROUND,\n",
            "text:\tWhile antidepressant drug treatment is likely to improve depressive symptoms , it crosses the placenta and may pose risks to the unborn child .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40544,\n",
            "target:BACKGROUND,\n",
            "text:\tTranscranial direct current stimulation is a focal brain stimulation treatment that improves depressive symptoms within @ weeks of treatment by inducing changes to brain areas involved in depression , without impacting any other brain areas , and without inducing changes to heart rate , blood pressure or core body temperature .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40545,\n",
            "target:BACKGROUND,\n",
            "text:\tThe localized nature of transcranial direct current stimulation makes it an ideal therapeutic approach for treating depression during pregnancy , although it has never previously been evaluated in this population .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40546,\n",
            "target:METHODS,\n",
            "text:\tWe describe a pilot randomized controlled trial of transcranial direct current stimulation among women with depression in pregnancy to assess the feasibility of a larger , multicentre efficacy study .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40547,\n",
            "target:METHODS,\n",
            "text:\tWomen over @ years of age and between @ and @ weeks gestation can be enrolled in the study provided they meet diagnostic criteria for a major depressive episode of at least moderate severity and have been offered but refused antidepressant medication .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40548,\n",
            "target:METHODS,\n",
            "text:\tParticipants are randomized to receive active transcranial direct current stimulation or a sham condition that is administered in @ @-minute treatments over three weeks .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40549,\n",
            "target:METHODS,\n",
            "text:\tWomen sit upright during treatment and receive obstetrical monitoring prior to , during and after each treatment session .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40550,\n",
            "target:METHODS,\n",
            "text:\tDepressive symptoms , treatment acceptability , and pregnancy outcomes are assessed at baseline ( prior to randomization ) , at the end of each treatment week , every four weeks post-treatment until delivery , and at @ and @ weeks postpartum .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40551,\n",
            "target:CONCLUSION,\n",
            "text:\tTranscranial direct current stimulation is a novel therapeutic option for treating depression during pregnancy .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40552,\n",
            "target:CONCLUSION,\n",
            "text:\tThis protocol allows for assessment of the feasibility of , acceptability of and adherence with a clinical trial protocol to administer this treatment to pregnant women with moderate to severe depression .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40553,\n",
            "target:CONCLUSION,\n",
            "text:\tResults from this pilot study will guide the development of a larger multicentre trial to definitively test the efficacy and safety of transcranial direct current stimulation for pregnant women with depression .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40554,\n",
            "target:BACKGROUND,\n",
            "text:\tClinical Trials Gov NCT@ .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40555,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40557,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo compare the analgesic effect of ultrasound-guided Transversus Abdominis Plane ( TAP ) block versus Continuous Wound Infusion ( CWI ) with levobupivacaine after caesarean delivery .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40558,\n",
            "target:METHODS,\n",
            "text:\tWe recruited parturients undergoing elective caesareans for this multicenter study .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40559,\n",
            "target:METHODS,\n",
            "text:\tFollowing written informed consent , they received a spinal anaesthetic without intrathecal morphine for their caesarean section .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40560,\n",
            "target:METHODS,\n",
            "text:\tThe postoperative analgesia was randomized to either a bilateral ultrasound guided TAP block ( levobupivicaine = @ mg ) or a CWI through an elastomeric pump for @ hours ( levobupivacaine = @ mg the first day and @ mg/h thereafter ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40561,\n",
            "target:METHODS,\n",
            "text:\tEvery woman received regular analgesics along with oral morphine if required .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40562,\n",
            "target:METHODS,\n",
            "text:\tThe primary outcome was comparison of the @-hour area under the curve ( AUC ) pain scores .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40563,\n",
            "target:METHODS,\n",
            "text:\tSecondary outcomes included morphine consumption , adverse events , and persistent pain one month postoperatively .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40564,\n",
            "target:RESULTS,\n",
            "text:\tRecruitment of @ women was planned but the study was prematurely terminated due to the occurrence of generalized seizures in one patient of the TAP group .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40565,\n",
            "target:RESULTS,\n",
            "text:\tBy then , @ patients with TAP and @ with CWI had completed the study .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40566,\n",
            "target:RESULTS,\n",
            "text:\tAUC of pain at rest and during mobilization were not significantly different : @ -LSB- @-@ -RSB- in TAP versus @ -LSB- @-@ -RSB- in CWI ( P = @ ) and @ -LSB- @-@ -RSB- versus @ -LSB- @-@ @ -RSB- ( P = @ ) , respectively .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40567,\n",
            "target:RESULTS,\n",
            "text:\tMorphine consumption ( @ -LSB- @-@ -RSB- mg in the TAP group and @ -LSB- @-@ @ -RSB- mg in the CWI group ( P = @ ) ) and persistent pain at one month were similar in both groups ( respectively @ % and @ % ( P = @ ) ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40568,\n",
            "target:CONCLUSION,\n",
            "text:\tIn cases of morphine-free spinal anesthesia for cesarean delivery , no difference between TAP block and CWI for postoperative analgesia was suggested .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40569,\n",
            "target:CONCLUSION,\n",
            "text:\tTAP block may induce seizures in this specific context .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40570,\n",
            "target:CONCLUSION,\n",
            "text:\tConsequently , such a technique after a caesarean section can not be recommended .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40571,\n",
            "target:BACKGROUND,\n",
            "text:\tClinicalTrials.gov NCT@ .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40572,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40574,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe objective was to determine whether adding a self-regulatory intervention ( SRI ) focused on self-monitoring of spontaneous physical activity ( SPA ) and sedentary behavior to a standard weight loss intervention improved maintenance of lost weight .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40575,\n",
            "target:METHODS,\n",
            "text:\tOlder ( @-@ years ) , obese ( BMI = @-@ kg/m ( @ ) ) adults ( n = @ ) were randomized to a @-month weight loss intervention involving a hypocaloric diet ( DIET ) and aerobic exercise ( EX ) with or without the SRI to promote SPA and decrease sedentary behavior ( SRI+DIET+EX compared with DIET+EX ) .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40576,\n",
            "target:METHODS,\n",
            "text:\tFollowing the weight loss phase , both groups transitioned to self-selected diet and exercise behavior during a @-month follow-up .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40577,\n",
            "target:METHODS,\n",
            "text:\tThroughout the @-months , the SRI+DIET+EX group utilized real-time accelerometer feedback for self-monitoring .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40578,\n",
            "target:RESULTS,\n",
            "text:\tThere was an overall group by time effect of the SRI ( P < @ ) ; DIET+EX lost less weight and regained more weight than SRI+DIET+EX .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40579,\n",
            "target:RESULTS,\n",
            "text:\tThe average weight regain during follow-up was @ kg less in the SRI+DIET+EX group .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40580,\n",
            "target:RESULTS,\n",
            "text:\tIndividuals in this group maintained approximately @ % lower weight than baseline compared with those in the DIET+EX group whom maintained approximately @ % lower weight than baseline .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40581,\n",
            "target:CONCLUSION,\n",
            "text:\tAddition of a SRI , designed to increase SPA and decrease sedentary behavior , to a standard weight loss intervention enhanced successful maintenance of lost weight .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40582,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40584,\n",
            "target:BACKGROUND,\n",
            "text:\tPhenylephrine infusion is used to reduce hypotension during spinal anesthesia for cesarean delivery .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40585,\n",
            "target:BACKGROUND,\n",
            "text:\tA prophylactic fixed rate infusion regimen may not improve hemodynamic control ; a variable rate regimen adjusted in response to changes in arterial blood pressure and heart rate may allow more accurate maintenance of baseline blood pressure .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40586,\n",
            "target:BACKGROUND,\n",
            "text:\tWe hypothesized that a combination of crystalloid solution coload with a variable rate phenylephrine infusion and phenylephrine rescue boluses may be associated with fewer physician interventions needed to maintain maternal systolic blood pressure within @ % of baseline and greater hemodynamic stability than crystalloid solution coload with phenylephrine rescue boluses alone .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40587,\n",
            "target:METHODS,\n",
            "text:\tIn this prospective , double-blind study , @ patients received a coload with @ mL/kg lactated Ringer 's solution immediately after the initiation of spinal anesthesia .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40588,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomized to receive a prophylactic variable rate phenylephrine infusion starting at @ g/kg/min ( group P ) or infusion of normal saline ( group S ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40589,\n",
            "target:METHODS,\n",
            "text:\tMaternal systolic blood pressure was maintained within @ % of baseline with rescue phenylephrine boluses using a preset algorithm .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40590,\n",
            "target:METHODS,\n",
            "text:\tDuring the predelivery period , the number of physician interventions ( primary outcome ) , hemodynamic performance , nausea/vomiting , and umbilical cord blood gas values were compared between the groups .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40591,\n",
            "target:RESULTS,\n",
            "text:\tOne patient from group S was excluded due to protocol violation .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40592,\n",
            "target:RESULTS,\n",
            "text:\tTherefore , group P included @ patients and group S @ patients .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40593,\n",
            "target:RESULTS,\n",
            "text:\tThe median ( range ) number of physician interventions needed to maintain maternal hemodynamics within the target range ( @ -LSB- @-@ -RSB- vs @ -LSB- @-@ -RSB- , difference in median : @ , @ % confidence interval of difference : @-@ ) and incidence of hypotension ( @/@ -LSB- @ % -RSB- vs @/@ -LSB- @ % -RSB- ) were lower in group P compared with group S ( P < @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40594,\n",
            "target:RESULTS,\n",
            "text:\tGroup P had a higher incidence of hypertension compared with group S ( @/@ -LSB- @ % -RSB- vs @/@ -LSB- @ % -RSB- , P = @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40595,\n",
            "target:RESULTS,\n",
            "text:\tThe median performance error was closer to baseline ( P < @ ) with a smaller median absolute performance error ( P = @ ) in group P versus group S.,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40596,\n",
            "target:RESULTS,\n",
            "text:\tIn group P , @/@ ( @ % ) patients had nausea/vomiting compared with @/@ ( @ % ) in group S ( P = @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40597,\n",
            "target:RESULTS,\n",
            "text:\tThe number needed to treat was @ women to prevent @ case of hypotension , and @ women to prevent @ case of nausea/vomiting ; the rate of hypertension was @ case per @ women treated .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40598,\n",
            "target:RESULTS,\n",
            "text:\tNeonatal outcomes were not different between the @ groups .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40599,\n",
            "target:CONCLUSION,\n",
            "text:\tProphylactic variable rate phenylephrine infusion and rescue phenylephrine bolus dosing is more effective than relying on rescue phenylephrine bolus dosing with respect to limiting clinician workload and maternal symptoms during spinal anesthesia for cesarean delivery .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40600,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40602,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe aim of this study is to describe implementation of a randomized controlled trial of community-based participatory research ( CBPR ) approaches to increase park use and physical activity across @ diverse neighborhoods in Los Angeles .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40603,\n",
            "target:METHODS,\n",
            "text:\tFifty parks were randomly assigned based on park size , facilities and programs , and neighborhood socio-demographic characteristics to : park director ( PD , @ parks ) ; PD and park advisory board of interested community members ( PD+PAB , @ parks ) ; and no-intervention control ( @ parks ) arms .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40604,\n",
            "target:METHODS,\n",
            "text:\tBetween @ and @ , PDs and PABs from the @ intervention parks participated in community engagement , baseline assessment , marketing training , intervention design and implementation , and follow-up assessment .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40605,\n",
            "target:RESULTS,\n",
            "text:\tIntervention parks ( PD and PD+PAB ) invested in new and diversified signage , promotional items , outreach or support for group activities like fitness classes and walking clubs , and various marketing strategies .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40606,\n",
            "target:RESULTS,\n",
            "text:\tScaling up CBPR methods across parks in @ diverse neighborhoods was challenging .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40607,\n",
            "target:RESULTS,\n",
            "text:\tWorking with departmental management and established structures for community input ( PABs ) and park policy ( PDs ) facilitated implementation and sustainability .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40608,\n",
            "target:CONCLUSION,\n",
            "text:\tScaling up CBPR methods across diverse communities involved tradeoffs .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40609,\n",
            "target:CONCLUSION,\n",
            "text:\tCBPR is useful for tailoring research and enhancing community impact and sustainability , but more work is needed to understand how to conduct multi-site trials across diverse settings using CBPR .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40610,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40612,\n",
            "target:OBJECTIVE,\n",
            "text:\tPosterior-cruciate-ligament-retaining ( PCR ) and posterior-cruciate-ligament-stabilized ( PS ) arthroplasties are two major common practices in total knee arthroplasty ( TKA ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40613,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe hypothesis of the present study was that compared with the PCR technique , the PS technique is associated with a higher amount of postoperative blood loss and greater need for blood transfusion in cemented TKA .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40614,\n",
            "target:METHODS,\n",
            "text:\tIn this prospective , randomized study , @ patients diagnosed with primary knee osteoarthritis were randomly assigned to either the PCR group ( Group I ) or the PS group ( Group II ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40615,\n",
            "target:METHODS,\n",
            "text:\tThe exclusion criteria were rheumatological joint disease , previous knee surgery , anticoagulant therapy and hypertension .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40616,\n",
            "target:METHODS,\n",
            "text:\tThere were no significant differences in age , body mass index and gender , between the groups .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40617,\n",
            "target:METHODS,\n",
            "text:\tThe haemoglobin and haematocrit levels of each patient were recorded preoperatively and on postoperative days @ , @ and @ .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40618,\n",
            "target:METHODS,\n",
            "text:\tThe postoperative suction drainage and blood transfusion volumes were also recorded .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40619,\n",
            "target:RESULTS,\n",
            "text:\tThere were no statistically significant differences in haemoglobin or haematocrit levels between the groups on postoperative days @ , @ and @ .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40620,\n",
            "target:RESULTS,\n",
            "text:\tThere were also no statistically significant differences in the total measured blood loss volume , postoperative drainage amounts or transfusion rates between the groups .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40621,\n",
            "target:CONCLUSION,\n",
            "text:\tUse of the PS technique during cemented TKA does not appear to influence the amount of perioperative blood loss or the need for postoperative blood transfusion in general .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40622,\n",
            "target:CONCLUSION,\n",
            "text:\tThe clinical relevance of this study is that the difference in blood loss between the PCR and PS techniques does not need to be considered by surgeons when performing TKA .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40623,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40625,\n",
            "target:BACKGROUND,\n",
            "text:\tRadical retropubic prostatectomy ( RRP ) is associated with an increased risk of intraoperative blood loss and the necessity of transfusions .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40626,\n",
            "target:BACKGROUND,\n",
            "text:\tThis prospective randomised clinical study evaluates the influence of thoracic epidural analgesia ( TEA ) on blood loss in RRP .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40627,\n",
            "target:METHODS,\n",
            "text:\t@ patients were randomised : TEA in group @ ( n = @ ; general anaesthesia + TEA ) comprised continuous administration of @ % bupivacaine , while group @ ( n = @ ; general anaesthesia alone ) received intravenous analgesia with fentanyl ( intubation : @ g/kg ; maintenance : @-@ @ mg ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40628,\n",
            "target:METHODS,\n",
            "text:\tA restrictive infusion regimen ( < @,@ ml until specimen removal ) was administered in both groups .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40629,\n",
            "target:METHODS,\n",
            "text:\tBlood loss , infusion rates and anaesthesiological parameters were recorded and analysed using regression models and analyses of variance .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40630,\n",
            "target:RESULTS,\n",
            "text:\tHaemoglobin difference between the pre - and the first postoperative day ( group @ : @ @ g/dl ; group @ : @ @ g/dl ; p = @ ) , overall blood loss ( group @ : @ @ ml ; group @ : @ @ ml ; p = @ ) and transfusion rates ( @ % intraoperatively ; @ % postoperatively ; p = @ ) did not show group differences .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40631,\n",
            "target:RESULTS,\n",
            "text:\tIn regression analysis blood loss was influenced by preoperative haemoglobin levels ( p < @ ) , patients ' weight ( p = @ ) and duration of the operation ( p = @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40632,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study did not demonstrate a direct impact of TEA on intraoperative blood loss and transfusion rates in RRP .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40633,\n",
            "target:CONCLUSION,\n",
            "text:\tFurther randomised clinical trials are needed to evaluate an impact of the different anaesthetic procedures presented alone or in combination on blood loss .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40634,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40636,\n",
            "target:BACKGROUND,\n",
            "text:\tCurrently , short-axis out-of-plane ( SA-OOP ) and long-axis in-plane ( LA-IP ) ultrasound techniques are used to guide radial artery cannulation .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40637,\n",
            "target:BACKGROUND,\n",
            "text:\tIn this study , we compared the success rate of a modified SA-OOP technique with that of traditional LA-IP .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40638,\n",
            "target:METHODS,\n",
            "text:\tOne hundred sixty-four patients who were to undergo liver surgery or splenic resection under general anesthesia were included .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40639,\n",
            "target:METHODS,\n",
            "text:\tUsing a sealed envelope method , patients were randomly divided into @ groups : the modified SA-OOP or the LA-IP ultrasound guidance approaches .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40640,\n",
            "target:METHODS,\n",
            "text:\tThe number of cannula insertion attempts until success was recorded in both groups .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40641,\n",
            "target:METHODS,\n",
            "text:\tThe primary end point to compare the groups was the rate of cannula insertion successes on the first attempt .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40642,\n",
            "target:METHODS,\n",
            "text:\tThe secondary end points were also recorded and compared : insertion failure rate , inner diameter of the radial artery , depth of artery from the skin , ultrasonic location time , cannulation time , and vascular complications including thrombosis , hematoma , edema , and vasospasm .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40643,\n",
            "target:RESULTS,\n",
            "text:\tThe cannula insertion success rate on the first attempt was significantly higher in the modified SA-OOP group compared with the LA-IP group ( proportion difference @ % , @ % confidence interval -LSB- CI -RSB- , @ % -@ % , P = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40644,\n",
            "target:RESULTS,\n",
            "text:\tHowever , the insertion failure rate was not different between groups ( @ % CI , -@ % to @ % , P = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40645,\n",
            "target:RESULTS,\n",
            "text:\tThe ultrasonic location time was significantly decreased in the modified SA-OOP group compared with the LA-IP group ( mean difference -@ seconds , @ % CI , -@ to -@ seconds , P < @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40646,\n",
            "target:RESULTS,\n",
            "text:\tHowever , there was no significant difference between groups for cannulation time ( @ % CI , -@ to @ seconds , P = @ ) , depth of artery ( @ % CI , -@ to @ mm , P = @ ) , and the diameter of the radial artery ( @ % CI , -@ to @ mm , P = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40647,\n",
            "target:CONCLUSION,\n",
            "text:\tThe modified SA-OOP technique may improve the success rate of cannula insertion into the radial artery on the first attempt .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40648,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40650,\n",
            "target:OBJECTIVE,\n",
            "text:\tChemotherapy-induced diarrhea ( CID ) is a relatively common adverse event in the treatment of patients with colorectal cancer .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40651,\n",
            "target:OBJECTIVE,\n",
            "text:\tThe LAR for Chemotherapy-Induced Diarrhea ( LARCID ) trial evaluated the efficacy and safety of long-acting release octreotide ( octreotide LAR ) for the prevention of CID in this population .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40652,\n",
            "target:METHODS,\n",
            "text:\tPatients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil , capecitabine , and/or irinotecan were randomly assigned to receive octreotide LAR @ mg intramuscularly every @ weeks ( experimental arm ) or the physician 's treatment of choice in case of diarrhea ( control arm ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40653,\n",
            "target:RESULTS,\n",
            "text:\tA total of @ patients were randomly assigned , most of whom received fluorouracil - and oxaliplatin-containing chemotherapy regimens .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40654,\n",
            "target:RESULTS,\n",
            "text:\tThe rate of diarrhea was @ % in the experimental group ( n = @ ) and @ % in the control group ( n = @ ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40655,\n",
            "target:RESULTS,\n",
            "text:\tTreatment with octreotide LAR did not prevent or reduce the severity of CID .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40656,\n",
            "target:RESULTS,\n",
            "text:\tTreatment choices for diarrhea management included loperamide in the majority of patients .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40657,\n",
            "target:RESULTS,\n",
            "text:\tNo benefit from octreotide LAR was identified in terms of need for diarrhea treatment , opioids , or intravenous hydration or in the rate of hospitalization or quality of life .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40658,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study could not prove the efficacy of octreotide LAR in the prevention of CID .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40659,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40661,\n",
            "target:BACKGROUND,\n",
            "text:\tTreatment with rituximab may be accompanied by a systemic cytokine release .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40662,\n",
            "target:BACKGROUND,\n",
            "text:\tWe studied the effects of a single dose of rituximab on cytokine levels in transplant patients and examined the underlying mechanism .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40663,\n",
            "target:METHODS,\n",
            "text:\tTwenty renal transplant recipients ( @ rituximab-treated , @ placebo-treated ) were recruited from a randomized clinical trial .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40664,\n",
            "target:METHODS,\n",
            "text:\tRituximab or placebo was infused during surgery , and blood samples were taken before , during , and after surgery and analyzed for interleukin ( IL ) -@ , IL-@ , IL-@ , IL-@ , IL-@ , IL-@ , interferon - , macrophage inflammatory protein ( MIP ) -@ , transforming growth factor - , and tumor necrosis factor - .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40665,\n",
            "target:METHODS,\n",
            "text:\tin vitro , healthy donor peripheral blood mononuclear cells , purified B cells , monocytes , natural killer ( NK ) cells , or combinations thereof were incubated with rituximab , rituximab-F ( ab ' ) @ , or medium and MIP-@ , IL-@ , interferon - , and tumor necrosis factor - levels were measured in the supernatant .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40666,\n",
            "target:RESULTS,\n",
            "text:\tRituximab-treated patients had higher serum levels of IL-@ ( @ @ pg/mL vs @ @ pg/mL ; P < @ ) and MIP-@ ( @ @ pg/mL vs @ @ pg/mL ; P < @ ) compared to placebo-treated patients at @ hours after start of infusion .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40667,\n",
            "target:RESULTS,\n",
            "text:\tThere was no difference in the level of other cytokines .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40668,\n",
            "target:RESULTS,\n",
            "text:\tIn vitro , the addition of rituximab , but not rituximab-F ( ab ' ) @ fragments , only led to significantly increased levels of MIP-@ in co-cultures of B and NK cells .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40669,\n",
            "target:RESULTS,\n",
            "text:\tLevels of MIP-@ were higher in patients with a high affinity Fc-receptor compared to those with a lower affinity FcRIIIa ( @ @ pg/mL vs @ @ pg/mL ; P < @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40670,\n",
            "target:CONCLUSION,\n",
            "text:\tIn addition to B-cell depletion , rituximab can modulate the immune response by inducing cytokine secretion , especially IL-@ and MIP-@ .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40671,\n",
            "target:CONCLUSION,\n",
            "text:\tRituximab-induced MIP-@ secretion depends on the combined presence of B cells and FcR-bearing cells , especially NK cells .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40672,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40674,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo compare a new low-dose levonorgestrel and ethinyl estradiol contraceptive patch ( Patch ) with a combination oral contraceptive ( Pill ; @ micrograms levonorgestrel , @ micrograms ethinyl estradiol ) regarding efficacy , safety , compliance , and unscheduled uterine bleeding .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40675,\n",
            "target:METHODS,\n",
            "text:\tWomen ( @-@ years ; body mass index @-@ ) were randomized in a @:@ ratio to one of two groups : Patch only ( @ cycles ) or Pill ( six cycles ) followed by Patch ( seven cycles ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40676,\n",
            "target:METHODS,\n",
            "text:\tInvestigators evaluated adverse events during cycles @ , @ , @ , @ , and @ .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40677,\n",
            "target:METHODS,\n",
            "text:\tParticipants recorded drug administration and uterine bleeding on daily diary cards .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40678,\n",
            "target:METHODS,\n",
            "text:\tCompliance was assessed by measuring levonorgestrel and ethinyl estradiol plasma levels .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40679,\n",
            "target:METHODS,\n",
            "text:\tPearl Index ( pregnancies per @ woman-years ) was calculated to evaluate efficacy .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40680,\n",
            "target:RESULTS,\n",
            "text:\tParticipants ( N = @,@ ) were randomized to Patch ( n = @,@ ) or Pill ( n = @ ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40681,\n",
            "target:RESULTS,\n",
            "text:\tApproximately @ % were obese , more than @ % were racial or ethnic minorities , and more than @ % were new users of hormonal contraceptives .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40682,\n",
            "target:RESULTS,\n",
            "text:\tLaboratory-verified noncompliance ( undetectable plasma drug levels ) was @ % of Patch and @ % of Pill users at cycle @ .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40683,\n",
            "target:RESULTS,\n",
            "text:\tPearl Indices ( @ % confidence intervals ) for the intention-to-treat population ( cycles @-@ ) were @ ( @-@ @ ) for Patch and @ ( @-@ @ ) for Pill ; excluding laboratory-verified noncompliant participants , Pearl Indices were @ ( @-@ @ ) for Patch and @ ( @-@ @ ) for Pill ( differences not statistically significant ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40684,\n",
            "target:RESULTS,\n",
            "text:\tIncidence of unscheduled bleeding and incidence and severity of adverse events were similar for both contraceptives ( no statistically significant difference ) .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40685,\n",
            "target:CONCLUSION,\n",
            "text:\tEfficacy and safety of the new contraceptive Patch are comparable to those of a Pill .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40686,\n",
            "target:CONCLUSION,\n",
            "text:\tLaboratory-verified noncompliance and bleeding profile are similar between the two treatments .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40687,\n",
            "target:CONCLUSION,\n",
            "text:\tThe Patch was well tolerated .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40688,\n",
            "target:BACKGROUND,\n",
            "text:\tClinicalTrials.gov , www.clinicaltrials.gov , NCT@ .,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40689,\n",
            "target:METHODS,\n",
            "text:\tI.,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40690,\n",
            "target:METHODS,\n",
            "text:,\n",
            "total_line:17]\n",
            "\n",
            "\n",
            "[line_number:40692,\n",
            "target:OBJECTIVE,\n",
            "text:\tEndocrine therapies include aromatase inhibitors and the selective estrogen receptor ( ER ) downregulator fulvestrant .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40693,\n",
            "target:OBJECTIVE,\n",
            "text:\tThis study aimed to determine whether the reported efficacy of fulvestrant over anastrozole , and high - over low-dose fulvestrant , reflect distinct transcriptional responses .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40694,\n",
            "target:METHODS,\n",
            "text:\tGlobal gene expression profiles from ER-positive breast carcinomas before and during presurgical treatment with fulvestrant ( n = @ ) or anastrozole ( n = @ ) , and corresponding in vitro models , were compared .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40695,\n",
            "target:METHODS,\n",
            "text:\tTranscripts responding differently to fulvestrant and estrogen deprivation were identified and integrated using Gene Ontology , pathway and network analyses to evaluate their potential significance .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40696,\n",
            "target:RESULTS,\n",
            "text:\tThe overall transcriptional response to fulvestrant and estrogen deprivation was correlated ( r = @ in presurgical studies , r = @ in vitro ) , involving downregulation of estrogen-regulated and proliferation-associated genes .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40697,\n",
            "target:RESULTS,\n",
            "text:\tThe transcriptional response to fulvestrant was of greater magnitude than estrogen deprivation ( slope = @ in presurgical studies , slope = @ in vitro ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40698,\n",
            "target:RESULTS,\n",
            "text:\tComparative analyses identified @ genes and @ Gene Ontology categories affected differentially by fulvestrant .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40699,\n",
            "target:RESULTS,\n",
            "text:\tSeventeen fulvestrant-specific genes , including CAV@/@ , SNAI@ , and NRP@ , associated with ER , androgen receptor ( AR ) , and TP@ , in a network regulating cell cycle , death , survival , and tumor morphology .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40700,\n",
            "target:RESULTS,\n",
            "text:\tEighteen genes responding differently to fulvestrant specifically predicted antiproliferative response to fulvestrant , but not anastrozole .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40701,\n",
            "target:RESULTS,\n",
            "text:\tTranscriptional effects of low-dose fulvestrant correlated with high-dose treatment , but were of lower magnitude ( ratio = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40702,\n",
            "target:CONCLUSION,\n",
            "text:\tThe transcriptional response to fulvestrant has much in common with estrogen deprivation , but is stronger with distinctions potentially attributable to arrest of estrogen-independent ER activity and involvement of AR signaling .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40703,\n",
            "target:CONCLUSION,\n",
            "text:\tGenes responding differently to fulvestrant may have predictive utility .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40704,\n",
            "target:CONCLUSION,\n",
            "text:\tThese data are consistent with the clinical efficacy of fulvestrant versus anastrozole and higher dosing regimens .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40705,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40707,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo compare the impact of varying fluidic parameters on intraoperative intraocular pressure ( IOP ) fluctuations and postoperative outcomes .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40708,\n",
            "target:METHODS,\n",
            "text:\tProspective randomized study of @ eyes undergoing cataract surgery that were randomly assigned to low ( aspiration flow rate : @ cc/min ; bottle height : @ cm ; vacuum : @ mm Hg ) and high ( aspiration flow rate : @ cc/min ; bottle height : @ cm ; vacuum : @ mm Hg ) fluidic parameter groups .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40709,\n",
            "target:METHODS,\n",
            "text:\tReal-time dynamic intraoperative IOP was measured during nuclear fragment removal .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40710,\n",
            "target:METHODS,\n",
            "text:\tMean maximum and minimum IOP and percentage reduction in IOP from maximum were compared between groups .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40711,\n",
            "target:METHODS,\n",
            "text:\tPostoperatively , the rate of change in central corneal thickness and anterior chamber inflammation at days @ and @ , endothelial cell density at @ months , and corneal clarity on day @ were compared .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40712,\n",
            "target:RESULTS,\n",
            "text:\tMinimum IOP in the low and high parameters groups was @ @ and @ @ mm Hg , respectively .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40713,\n",
            "target:RESULTS,\n",
            "text:\tMaximum IOP in the low and high parameters groups was @ @ and @ @ mm Hg , respectively ( P < @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40714,\n",
            "target:RESULTS,\n",
            "text:\tMean percent reduction from maximum was @ % in the high parameters group compared to @ % in the low parameters group , with the difference being statistically significant ( P < @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40715,\n",
            "target:RESULTS,\n",
            "text:\tRate of change in central corneal thickness was greater in the high parameters group at postoperative days @ and @ ( P < @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40716,\n",
            "target:RESULTS,\n",
            "text:\tAnterior chamber inflammation and corneal clarity on the first postoperative day were significantly better in the low parameters group .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40717,\n",
            "target:CONCLUSION,\n",
            "text:\tHigher aspiration flow rate and bottle heights are associated with high intraoperative IOPs of up to @ mm Hg .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40718,\n",
            "target:CONCLUSION,\n",
            "text:\tProlonged elevated IOP during cataract surgery was found to have more anterior segment inflammation and more edematous corneas .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40719,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40721,\n",
            "target:OBJECTIVE,\n",
            "text:\tWe compare monopolar vs bipolar transurethral resection of the prostate in patients with benign prostatic hyperplasia , focusing on functional outcomes as well as rates of bleeding complications and the transurethral resection syndrome .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40722,\n",
            "target:METHODS,\n",
            "text:\tA total of @ patients with benign prostatic hyperplasia ( mean age @ years , range @ to @ ) were prospectively randomly assigned to undergo monopolar ( @ ) or bipolar ( @ ) transurethral resection of the prostate .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40723,\n",
            "target:METHODS,\n",
            "text:\tPatient characteristics of the @ groups were similar .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40724,\n",
            "target:METHODS,\n",
            "text:\tHemoglobin ( as a marker of blood loss ) was measured preoperatively and perioperatively .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40725,\n",
            "target:METHODS,\n",
            "text:\tI-PSS , I-PSS-QoL score , maximal flow rate and post-void residual urine volume were assessed preoperatively and @ and @ months postoperatively .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40726,\n",
            "target:METHODS,\n",
            "text:\tDuration of surgery , indwelling catheter use and hospitalization were also documented , as were postoperative clot retention requiring removal by catheterization or surgery , and rates of bladder neck and/or urethral strictures .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40727,\n",
            "target:RESULTS,\n",
            "text:\tNo significant perioperative differences were found in duration of surgery , catheterization or hospitalization , or in blood loss or rates of blood transfusion and transurethral resection syndrome .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40728,\n",
            "target:RESULTS,\n",
            "text:\tPostoperatively there were no significant differences in I-PSS or I-PSS-QoL scores , or rates of rehospitalization , clot retention , blood transfusions , reoperation or urethral strictures .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40729,\n",
            "target:RESULTS,\n",
            "text:\tHowever , bladder neck stricture occurred significantly more often in the bipolar group ( @ % vs @ % , p = @ ) .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40730,\n",
            "target:RESULTS,\n",
            "text:\tThe @ and @-month followup showed significant and equal improvement in micturition in the @ groups .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40731,\n",
            "target:CONCLUSION,\n",
            "text:\tBipolar and monopolar transurethral resection of the prostate are effective and safe techniques for the surgical treatment of benign prostatic hyperplasia .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40732,\n",
            "target:CONCLUSION,\n",
            "text:\tThe only significant difference between them was a significantly higher rate of bladder neck strictures with bipolar resection of the prostate .,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40733,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:13]\n",
            "\n",
            "\n",
            "[line_number:40735,\n",
            "target:OBJECTIVE,\n",
            "text:\tThis study aimed ( @ ) to determine whether scanner arm rotation causes significant movement of the head restraint and ( @ ) to measure patient movement and its variation during the scan .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40736,\n",
            "target:METHODS,\n",
            "text:\tThe iCAT scanner and a high-speed camera were used .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40737,\n",
            "target:METHODS,\n",
            "text:\tThe @ patients were divided into @ groups : the open-eyed group and the blindfolded group .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40738,\n",
            "target:RESULTS,\n",
            "text:\tThe mean level of head restraint movement was @ mm , with a significantly higher level at the beginning , probably owing to the accelerating arm .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40739,\n",
            "target:RESULTS,\n",
            "text:\tMean movement of patients was @ mm and @ mm in the open-eyed and blindfolded groups , respectively .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40740,\n",
            "target:RESULTS,\n",
            "text:\tPatient movement was also significantly higher at the beginning of the scan , when noise and vibrations are likely to surprise the patient .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40741,\n",
            "target:CONCLUSION,\n",
            "text:\tPatient instruction and a dry-run scan should be done by clinicians .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40742,\n",
            "target:CONCLUSION,\n",
            "text:\tManufacturers should consider separating the seat and head restraint from the rest of the scanner to avoid vibration transfer .,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40743,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:9]\n",
            "\n",
            "\n",
            "[line_number:40745,\n",
            "target:BACKGROUND,\n",
            "text:\tThe objective of this prospectively randomized phase II trial ( Trial registration : EUCTR@-@-@-DE ) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone ( LET ) or letrozole and zoledronic acid ( LET + ZOL ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40746,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomly assigned to receive either LET @ mg/day ( n = @ ) or the combination of LET @ mg/day and a total of seven infusions of ZOL @ mg every @ weeks ( n = @ ) for @ months .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40747,\n",
            "target:METHODS,\n",
            "text:\tPrimary endpoint was clinical response rate as assessed by mammogram readings .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40748,\n",
            "target:METHODS,\n",
            "text:\tThe study was terminated prematurely due to insufficient recruitment .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40749,\n",
            "target:METHODS,\n",
            "text:\tWe report here on an exploratory analysis of this data .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40750,\n",
            "target:RESULTS,\n",
            "text:\tCentral assessment of tumor sizes during the treatment period was available for @ patients ( @ LET , @ LET + ZOL ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40751,\n",
            "target:RESULTS,\n",
            "text:\tClinical responses ( complete or partial ) were seen in @ % ( @ % CI : @-@ @ ) of the patients in the LET arm and @ % ( @ % CI : @-@ @ ) of those in the LET + ZOL arm ( P = @ ) .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40752,\n",
            "target:RESULTS,\n",
            "text:\tA multivariate model showed an OR of @ ( @ % CI : @-@ @ ) for the experimental arm .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40753,\n",
            "target:CONCLUSION,\n",
            "text:\tNo increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40754,\n",
            "target:CONCLUSION,\n",
            "text:\tHowever a trend towards a better reponse in the LET + ZOL arm could be observed .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40755,\n",
            "target:CONCLUSION,\n",
            "text:\tThis trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy , and it may support the evidence for a direct antitumor action of zoledronic acid .,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40756,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:12]\n",
            "\n",
            "\n",
            "[line_number:40758,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo evaluate the efficacy and safety of conversion to lacosamide @ mg/day monotherapy in adults with focal epilepsy .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40759,\n",
            "target:METHODS,\n",
            "text:\tThis historical-controlled , double-blind study ( NCT@ ) enrolled patients aged @-@ years on stable doses of @-@ antiepileptic drugs ( AEDs ) and experiencing @-@ partial-onset seizures per @ days during the @-week prospective Baseline .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40760,\n",
            "target:METHODS,\n",
            "text:\tPatients were randomized to lacosamide @ or @ mg/day ( @:@ ratio ) , starting at @ mg/day and titrated over @ weeks to randomized dose .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40761,\n",
            "target:METHODS,\n",
            "text:\tPatients then withdrew background AEDs over @ weeks and entered a @-week Monotherapy Phase .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40762,\n",
            "target:METHODS,\n",
            "text:\tThe primary assessment was the Kaplan-Meier-predicted percentage of patients on @ mg/day in the full analysis set ( FAS ) meeting @ predefined seizure-related exit criterion by day @ , compared with the historical-control threshold ( @ % ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40763,\n",
            "target:RESULTS,\n",
            "text:\tFour hundred twenty-five patients were enrolled and were eligible for safety analyses ( @ mg/day , n = @ ; @ mg/day , n = @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40764,\n",
            "target:RESULTS,\n",
            "text:\tA total of @ ( @ % ) of @ patients completed the Lacosamide Maintenance Phase ( combined AED Withdrawal and Monotherapy Phases ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40765,\n",
            "target:RESULTS,\n",
            "text:\tAmong @ patients in the @ mg/day group in the FAS , @ ( @ % ) met @ exit criterion ; the Kaplan-Meier-predicted exit percentage at day @ for @ mg/day ( @ % ; @ % confidence interval -LSB- CI -RSB- @-@ @ % ) was lower than the historical control .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40766,\n",
            "target:RESULTS,\n",
            "text:\tWhen exit events , withdrawal due to treatment-emergent adverse events ( TEAEs ) , and withdrawal due to lack of efficacy were summed ( n = @ ) , the predicted exit percentage ( @ % ; @ % CI @-@ @ % ) was also lower than the historical control .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40767,\n",
            "target:RESULTS,\n",
            "text:\tMost patients receiving @ mg/day reported some improvement on the Clinical Global Impression of Change ( @ % ) and Patient Global Impression of Change ( @ % ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40768,\n",
            "target:RESULTS,\n",
            "text:\tOverall , the most common ( > @ % ) TEAEs were dizziness ( @ % ) , headache ( @ % ) , nausea ( @ % ) , convulsion ( @ % ) , somnolence ( @ % ) , and fatigue ( @ % ) ; most ( @ % ) were mild-to-moderate in intensity .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40769,\n",
            "target:RESULTS,\n",
            "text:\tSeventy-two patients ( @ % ) discontinued due to TEAEs .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40770,\n",
            "target:RESULTS,\n",
            "text:\tSeventeen patients ( @ % , all receiving @ mg/day ) experienced serious AEs .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40771,\n",
            "target:CONCLUSION,\n",
            "text:\tLacosamide @ mg/day monotherapy was effective , with a favorable safety profile in patients with focal epilepsy .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40772,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40774,\n",
            "target:BACKGROUND,\n",
            "text:\tProlonged sitting time is detrimental for health .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40775,\n",
            "target:BACKGROUND,\n",
            "text:\tIndividuals with desk-based occupations tend to sit a great deal and sit-stand workstations have been identified as a potential strategy to reduce sitting time .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40776,\n",
            "target:BACKGROUND,\n",
            "text:\tHence , the objective of the current study was to examine the effects of using sit-stand workstations on office workers ' sitting time at work and over the whole day .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40777,\n",
            "target:METHODS,\n",
            "text:\tWe conducted a randomized controlled trial pilot with crossover design and waiting list control in Sydney , Australia from September @ to July @ ( n = @ ; @ % female ; mean age @ years ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40778,\n",
            "target:METHODS,\n",
            "text:\tParticipants used a sit-stand workstation for four weeks in the intervention condition .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40779,\n",
            "target:METHODS,\n",
            "text:\tIn the time-matched control condition , participants received nothing and crossed over to the intervention condition after four weeks .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40780,\n",
            "target:METHODS,\n",
            "text:\tThe primary outcomes , sitting , standing and walking time at work , were assessed before and after using the workstations with ActivPALs and self-report questionnaires .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40781,\n",
            "target:METHODS,\n",
            "text:\tSecondary outcomes , domain-specific sitting over the whole day , were assessed by self-report .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40782,\n",
            "target:METHODS,\n",
            "text:\tLinear mixed models estimated changes in outcomes adjusting for measurement time , study grouping and covariates .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40783,\n",
            "target:RESULTS,\n",
            "text:\tIntervention participants significantly reduced objectively assessed time spent sitting at work by @ min/workday ( @ % CI : -@ , -@ ) and increased standing time at work by @ min/workday ( @ % CI : @ , @ ) ; these changes were significant relative to controls ( p = @ and p < @ , respectively ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40784,\n",
            "target:RESULTS,\n",
            "text:\tTotal sitting time significantly declined in intervention participants ( -@ min/workday ; @ % CI : -@ , -@ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40785,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study shows that introducing sit-stand workstations in the office can reduce desk-based workers ' sitting time at work in the short term .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40786,\n",
            "target:CONCLUSION,\n",
            "text:\tLarger scale studies on more representative samples are needed to determine the public health impact of sit-stand workstations .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40787,\n",
            "target:BACKGROUND,\n",
            "text:\tACTRN@ .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40788,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40790,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo determine whether falls can be prevented with minimally supervised exercise targeting potentially remediable fall risk factors , i.e. , poor balance , reduced leg muscle strength , and freezing of gait , in people with Parkinson disease .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40791,\n",
            "target:METHODS,\n",
            "text:\tTwo hundred thirty-one people with Parkinson disease were randomized into exercise or usual-care control groups .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40792,\n",
            "target:METHODS,\n",
            "text:\tExercises were practiced for @ to @ minutes , @ times weekly for @ months .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40793,\n",
            "target:METHODS,\n",
            "text:\tPrimary outcomes were fall rates and proportion of fallers during the intervention period .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40794,\n",
            "target:METHODS,\n",
            "text:\tSecondary outcomes were physical ( balance , mobility , freezing of gait , habitual physical activity ) , psychological ( fear of falling , affect ) , and quality-of-life measures .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40795,\n",
            "target:RESULTS,\n",
            "text:\tThere was no significant difference between groups in the rate of falls ( incidence rate ratio -LSB- IRR -RSB- = @ , @ % confidence interval -LSB- CI -RSB- @-@ @ , p = @ ) or proportion of fallers ( p = @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40796,\n",
            "target:RESULTS,\n",
            "text:\tPreplanned subgroup analysis revealed a significant interaction for disease severity ( p < @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40797,\n",
            "target:RESULTS,\n",
            "text:\tIn the lower disease severity subgroup , there were fewer falls in the exercise group compared with controls ( IRR = @ , @ % CI @-@ @ , p < @ ) , while in the higher disease severity subgroup , there was a trend toward more falls in the exercise group ( IRR = @ , @ % CI @-@ @ , p = @ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40798,\n",
            "target:RESULTS,\n",
            "text:\tPostintervention , the exercise group scored significantly ( p < @ ) better than controls on the Short Physical Performance Battery , sit-to-stand , fear of falling , affect , and quality of life , after adjusting for baseline performance .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40799,\n",
            "target:CONCLUSION,\n",
            "text:\tAn exercise program targeting balance , leg strength , and freezing of gait did not reduce falls but improved physical and psychological health .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40800,\n",
            "target:CONCLUSION,\n",
            "text:\tFalls were reduced in people with milder disease but not in those with more severe Parkinson disease .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40801,\n",
            "target:METHODS,\n",
            "text:\tThis study provides Class III evidence that for patients with Parkinson disease , a minimally supervised exercise program does not reduce fall risk .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40802,\n",
            "target:METHODS,\n",
            "text:\tThis study lacked the precision to exclude a moderate reduction or modest increase in fall risk from exercise .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40803,\n",
            "target:BACKGROUND,\n",
            "text:\tAustralian New Zealand Clinical Trials Registry ( ACTRN@ ) .,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40804,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:15]\n",
            "\n",
            "\n",
            "[line_number:40806,\n",
            "target:OBJECTIVE,\n",
            "text:\tPlatelet aggregation is enhanced in firefighters following short bouts of work in thermal protective clothing ( TPC ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40807,\n",
            "target:OBJECTIVE,\n",
            "text:\tWe sought to determine if aspirin therapy before and/or following exertion in TPC prevents platelet activation .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40808,\n",
            "target:METHODS,\n",
            "text:\tIn a double-blind , placebo-controlled study , @ firefighters were randomized to receive daily therapy ( @ mg aspirin or placebo ) for @ days before and a single dose ( @ mg aspirin or placebo ) following exercise in TPC resulting in four potential assignments : aspirin before and after exercise ( AA ) , placebo before and after exercise ( PP ) , aspirin before and placebo after exercise ( AP ) , and placebo before and aspirin after exercise ( PA ) .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40809,\n",
            "target:METHODS,\n",
            "text:\tPlatelet closure time ( PCT ) was measured with a platelet function analyzer before the @-week treatment , after the @ week treatment period , immediately after exercise , and @ , @ , and @ minutes later .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40810,\n",
            "target:RESULTS,\n",
            "text:\tBaseline PCT did not differ between groups .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40811,\n",
            "target:RESULTS,\n",
            "text:\tPCT changed over time in all four groups ( p < @ ) rising to a median of > @ seconds -LSB- IQR @ , @ -RSB- in AA and > @ -LSB- @ , @ -RSB- in AP prior to exercise .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40812,\n",
            "target:RESULTS,\n",
            "text:\tFollowing exercise , median PCT decreased to in all groups .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40813,\n",
            "target:RESULTS,\n",
            "text:\tMedian PCT returned to > @ seconds @ minutes later in AA and AP and rose to @ seconds in PA @ minutes after exercise .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40814,\n",
            "target:CONCLUSION,\n",
            "text:\tDaily aspirin therapy blunts platelet activation during exertional heat stress and single-dose aspirin therapy following exertional heat stress reduces platelet activation within @ minutes .,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40815,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:10]\n",
            "\n",
            "\n",
            "[line_number:40817,\n",
            "target:OBJECTIVE,\n",
            "text:\tHyperglycemia improves when patients with type @ diabetes are placed on a weight-loss diet .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40818,\n",
            "target:OBJECTIVE,\n",
            "text:\tImprovement typically occurs soon after diet implementation .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40819,\n",
            "target:OBJECTIVE,\n",
            "text:\tThis rapid response could result from low fuel supply ( calories ) , lower carbohydrate content of the weight-loss diet , and/or weight loss per se .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40820,\n",
            "target:OBJECTIVE,\n",
            "text:\tTo differentiate these effects , glucose , insulin , C-peptide and glucagon were determined during the last @ h of a @-day period without food ( severe calorie restriction ) and a calorie-sufficient , carbohydrate-free diet .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40821,\n",
            "target:METHODS,\n",
            "text:\tSeven subjects with untreated type @ diabetes were studied .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40822,\n",
            "target:METHODS,\n",
            "text:\tA randomized-crossover design with a @-week washout period between arms was used .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40823,\n",
            "target:METHODS,\n",
            "text:\tResults from both the calorie-sufficient , carbohydrate-free diet and the @-day fast were compared with the initial standard diet consisting of @ % carbohydrate , @ % protein and @ % fat .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40824,\n",
            "target:RESULTS,\n",
            "text:\tThe overnight fasting glucose concentration decreased from @ ( standard diet ) to @ ( carbohydrate-free diet ) to @ mg/dl ( fasting ) .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40825,\n",
            "target:RESULTS,\n",
            "text:\tThe @ h glucose and insulin area responses decreased by @ % and @ % on day @ of the carbohydrate-free diet , and by @ % and @ % after fasting .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40826,\n",
            "target:RESULTS,\n",
            "text:\tOvernight basal insulin and glucagon remained unchanged .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40827,\n",
            "target:CONCLUSION,\n",
            "text:\tShort-term fasting dramatically lowered overnight fasting and @ h integrated glucose concentrations .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40828,\n",
            "target:CONCLUSION,\n",
            "text:\tCarbohydrate restriction per se could account for @ % of the reduction .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40829,\n",
            "target:CONCLUSION,\n",
            "text:\tInsulin could not entirely explain the glucose responses .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40830,\n",
            "target:CONCLUSION,\n",
            "text:\tIn the absence of carbohydrate , the net insulin response was @ % of the standard diet .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40831,\n",
            "target:CONCLUSION,\n",
            "text:\tGlucagon did not contribute to the metabolic adaptations observed .,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40832,\n",
            "target:CONCLUSION,\n",
            "text:,\n",
            "total_line:16]\n",
            "\n",
            "\n",
            "[line_number:40834,\n",
            "target:OBJECTIVE,\n",
            "text:\tExposure therapy in anorexia nervosa has preliminarily been shown to be effective for increasing food intake .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40835,\n",
            "target:OBJECTIVE,\n",
            "text:\tD-Cycloserine is a glutamatergic N-methyl-d-aspartate receptor agonist that has been shown to facilitate the benefits of exposure therapy for anxiety disorders by enhancing the emotional learning in the exposures ; therefore , we examined D-cycloserine-facilitation of exposure therapy to increase body mass index ( BMI ) in patients with anorexia nervosa .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40836,\n",
            "target:METHODS,\n",
            "text:\tParticipants ( N = @ ) with anorexia nervosa ( diagnosed via DSM-IV ) were recruited from a partial hospitalization eating disorder clinic between February @ and November @ .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40837,\n",
            "target:METHODS,\n",
            "text:\tParticipants were randomly assigned to receive exposure therapy plus D-cycloserine ( n = @ ) or placebo ( n = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40838,\n",
            "target:METHODS,\n",
            "text:\tParticipants completed psychoeducation and @ sessions of exposure therapy , with medication ( D-cycloserine vs placebo ) given prior to the first @ exposure sessions .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40839,\n",
            "target:METHODS,\n",
            "text:\tThey also completed a @-month follow-up .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40840,\n",
            "target:RESULTS,\n",
            "text:\tAs hypothesized , participants in the D-cycloserine group showed a significantly greater increase in BMI than those in the placebo group ( Wilk = @ , F@ ,@ = @ , P = @ , p ( @ ) = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40841,\n",
            "target:RESULTS,\n",
            "text:\tD-Cycloserine participants gained @ pounds relative to @ pounds in the placebo group .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40842,\n",
            "target:RESULTS,\n",
            "text:\tBoth groups experienced significantly decreased anxiety over the course of therapy ( Wilk = @ , F@ ,@ = @ , P = @ , p ( @ ) = @ ) .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40843,\n",
            "target:CONCLUSION,\n",
            "text:\tThis study preliminarily demonstrates that D-cycloserine facilitates exposure therapy for anorexia nervosa , leading to increased weight gain .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40844,\n",
            "target:CONCLUSION,\n",
            "text:\tA potential mechanism is that participants who receive D-cycloserine may generalize learning from within-session exposures to food intake during other similar meals , resulting in sustained increases in BMI .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40845,\n",
            "target:CONCLUSION,\n",
            "text:\tFurther research is needed to confirm these findings and test the putative mechanism that generalized learning from exposure therapy can increase BMI and stabilize a healthy weight .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40846,\n",
            "target:BACKGROUND,\n",
            "text:\tClinicalTrials.gov identifier : NCT@ .,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40847,\n",
            "target:BACKGROUND,\n",
            "text:,\n",
            "total_line:14]\n",
            "\n",
            "\n",
            "[line_number:40849,\n",
            "target:BACKGROUND,\n",
            "text:\tA fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-@ ( GLP-@ ) analogue liraglutide has been developed as a once-daily injection for the treatment of type @ diabetes .,\n",
            "total_line:16]\n",
            "\n",
            "\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "KeyboardInterrupt",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-37-72c3d8a983da>\u001b[0m in \u001b[0;36m<cell line: 1>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0md\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mpreprocess_text_with_line_num\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtrain_lines\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0md\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-34-a734c62fcaea>\u001b[0m in \u001b[0;36mpreprocess_text_with_line_num\u001b[0;34m(txtData)\u001b[0m\n\u001b[1;32m     28\u001b[0m                   \"total_line\":total_lines}\n\u001b[1;32m     29\u001b[0m       \u001b[0mdata\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mupdate_val\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 30\u001b[0;31m       \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mf\"[line_number:{linecount},\\ntarget:{target},\\ntext:{text},\\ntotal_line:{total_lines}]\\n\\n\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     31\u001b[0m     \u001b[0mlinecount\u001b[0m\u001b[0;34m+=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     32\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/ipykernel/iostream.py\u001b[0m in \u001b[0;36mwrite\u001b[0;34m(self, string)\u001b[0m\n\u001b[1;32m    400\u001b[0m             \u001b[0mis_child\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_is_master_process\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    401\u001b[0m             \u001b[0;31m# only touch the buffer in the IO thread to avoid races\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 402\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mpub_thread\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mschedule\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0;34m:\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_buffer\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mwrite\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mstring\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    403\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mis_child\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    404\u001b[0m                 \u001b[0;31m# mp.Pool cannot be trusted to flush promptly (or ever),\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/ipykernel/iostream.py\u001b[0m in \u001b[0;36mschedule\u001b[0;34m(self, f)\u001b[0m\n\u001b[1;32m    201\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_events\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mf\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    202\u001b[0m             \u001b[0;31m# wake event thread (message content is ignored)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 203\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_event_pipe\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mb''\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    204\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    205\u001b[0m             \u001b[0mf\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/zmq/sugar/socket.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, data, flags, copy, track, routing_id, group)\u001b[0m\n\u001b[1;32m    616\u001b[0m                 )\n\u001b[1;32m    617\u001b[0m             \u001b[0mdata\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mgroup\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mgroup\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 618\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mflags\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mflags\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcopy\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrack\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtrack\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    619\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    620\u001b[0m     def send_multipart(\n",
            "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.send\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.send\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket._send_copy\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/zmq/backend/cython/checkrc.pxd\u001b[0m in \u001b[0;36mzmq.backend.cython.checkrc._check_rc\u001b[0;34m()\u001b[0m\n",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "str1=\"###35279E\"\n",
        "x=\"###\" in str1\n",
        "x"
      ],
      "metadata": {
        "id": "pS-m8fQDUhoF",
        "outputId": "7f3e5018-4f02-4754-db47-9acc3a14cef9",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "l1=[\"BAKCGROUND\",\"obj\\n\",\"\\n\"]\n",
        "str2=\"BAKCGROUND \\n ribdiuabda oddnaoid.\\n\"\n",
        "for i in l1:\n",
        "  print(i)\n",
        "  if i in str2:\n",
        "    x=i\n",
        "s=str2.find(\"KC\")\n",
        "x,s"
      ],
      "metadata": {
        "id": "Vg8hF3R1XOzn",
        "outputId": "61f7a539-fccc-4ed4-f185-29282082312a",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 12,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "BAKCGROUND\n",
            "obj\n",
            "\n",
            "\n",
            "\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "('\\n', 2)"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "str2[0:2]"
      ],
      "metadata": {
        "id": "5qxYez7EZWlp",
        "outputId": "8c6364ec-6282-4a25-da8c-00ec444c8e34",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 36
        }
      },
      "execution_count": 13,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'BA'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 13
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "l1.index(\"\\n\")"
      ],
      "metadata": {
        "id": "Btk4aqJDbNQZ",
        "outputId": "b45fb56e-47a6-451c-febf-1da7a1c9eb35",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "2"
            ]
          },
          "metadata": {},
          "execution_count": 14
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "Szwf-AEZbxc1"
      },
      "execution_count": 14,
      "outputs": []
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.10.4"
    },
    "orig_nbformat": 4,
    "colab": {
      "provenance": [],
      "gpuType": "T4",
      "include_colab_link": true
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}